WO2016183310A1 - Autoantigens for diagnosis of rheumatoid arthritis - Google Patents
Autoantigens for diagnosis of rheumatoid arthritis Download PDFInfo
- Publication number
- WO2016183310A1 WO2016183310A1 PCT/US2016/032077 US2016032077W WO2016183310A1 WO 2016183310 A1 WO2016183310 A1 WO 2016183310A1 US 2016032077 W US2016032077 W US 2016032077W WO 2016183310 A1 WO2016183310 A1 WO 2016183310A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- filamin
- subject
- sulfatase
- acetylglucosamine
- peptides
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Definitions
- the present invention relates to the field of diagnostics using humoral and cellular autoimmune responses to disease-related autoantigens.
- it relates to autoantigenic biomarkers for rheumatoid arthritis.
- Rheumatoid arthritis is a chronic autoimmune disease of unknown cause that affects primary joints.
- Human leukocyte antigen - antigen D related (HLA-DR) molecules play a central role in autoimmune diseases, as first reported by McDevitt in 1974, (1) HLA-DR molecules are highly expressed in synovial tissue (ST), the target of the immune response in chronic inflammatory forms of arthritis, including rheumatoid arthritis (RA) and Lyme arthritis (LA) (2, 3).
- ST synovial tissue
- LA Lyme arthritis
- the greatest known genetic risk factors for these diseases are certain HLA-DR alleles (4).
- HLA-DR molecules present foreign or self- peptides to CD4+ T cells, leading to their activation (5).
- HLA-DR alleles including the HLA-DRB 1*0101 and 0401 alleles (6, 7) convey the greatest risk. These alleles code for a similar sequence of amino acids, called the RA shared epitope, which line the P4 pocket of the HLA-DR molecule.
- Anti-citrullinated protein antibodies (ACPA) which are specific for RA, are significantly more frequent in patients who have the shared epitope (8-13).
- synovial tissue shows marked synovial hypertrophy, vascular proliferation, mononuclear cell infiltration, and intense expression of HLA-DR molecules on synoviocytes and infiltrating cells (2, 3).
- the tissue is bathed in synovial fluid (SF), which contains a rich mixture of inflammatory cells, including large numbers of dendritic cells and macrophages; the latter also have increased expression of HLA-DR molecules (28, 29).
- SF synovial fluid
- the repertoire of specific self-peptides presented by HLA-DR molecules in synovial tissues in RA is unknown. Accordingly there is an unmet need of identifying autoantigens presented by HLA-DR and pathogenic T-cell epitopes in synovial tissues, synovial fluid as well as peripheral blood mononuclear cells of RA patients.
- aspects of the invention relate to a method of diagnosing rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, wherein immunological reactivity of the subject to one or more of filamin-A and N-acetylglucosamine-6-sulfatase, as compared to an appropriate control, indicates the subject has rheumatoid arthritis.
- the determining is by evaluating a a biological sample obtained from the subject for immunological reactivity with the one or more of filamin-A and N-acetylglucosamine-6- sulfatase.
- determining immunological reactivity is by detecting the presence of T cells reactive to one or more of filamin-A and N-acetylglucosamine-6- sulfatase, comprising the steps: a) stimulating peripheral blood mononuclear cells (PBMC) of the subject or the synovial fluid mononuclear cells (SFMC) of the subject in vitro with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, whole protein or polypeptide fragments; b) measuring T cell proliferation in vitro or secretion of IFN- ⁇ into cell culture supematants; and c) identifying the subject as having T cells reactive to one or more of filamin-A and N-acetylglucosamine-6-sulfatase when T cell proliferation or secretion of IFN- ⁇ is measured as significantly increased over that of an appropriate control.
- PBMC peripheral blood mononuclear cells
- SFMC synovial fluid mononu
- step b) is measuring T cell proliferation in vitro, and the subject is identified as having T cell reactive to one or more of filamin-A and N-acetylglucoasmine-6-sulfatase when T cell proliferation is measured as significantly increased over that of an appropriate control.
- step b) is measuring T cell secretion of IFN- ⁇ into cell culture supematants, and the subject is identified as having T cell reactive to one or more of filamin-A and N-acetylglucoasmine-6-sulfatase when secretion of IFN- ⁇ is measured as significantly increased over that of an appropriate control.
- determining immunological reactivity comprises determining if the subject has a B-cell response to one or more of filamin-A and N-acetylglucosamine-6-sulfatase resulting in the production of autoantibodies that specifically recognize the one or more filamin-A and N- acetylglucosamine-6-sulfatase, by contacting the sample with filamin-A protein or a polypeptide fragment thereof, and/or N-acetylglucosamine-6-sulfatase protein or a polypeptide fragment thereof, under conditions that allow an immunocomplex of the antibody and the filamin-A or N-acetylglucosamine-6- sulfatase form, and detecting the presence or absence of an immunocomplex, wherein the presence of an immunocomplex indicates the subject presents a B-cell response to filamin-A and/or N- acetylglucosamine-6-sulfatase and where
- the assay is an enzyme-linked immunosorbent assay (ELISA), agglutination test, direct immunofluorescence assay, indirect immunofluorescence assay, or an immunoblot assay.
- ELISA enzyme-linked immunosorbent assay
- agglutination test direct immunofluorescence assay
- indirect immunofluorescence assay indirect immunofluorescence assay
- immunoblot assay an immunoblot assay
- the polypeptide fragment of filamin-A comprises the amino acid sequence NPAEFVVNTSNAGAG (SEQ ID NO: 1) or an antigenic portion thereof.
- polypeptide fragment of N-acetylglucosamine-6-sulfatase comprises the amino acid sequence of FEPFFMMIATPAPH (SEQ ID NO: 2) or an antigenic portion thereof.
- the subject has been or is further tested for one or more of rheumatoid factor, anti-citrullinated protein antibodies (ACPA), and one or more HLA-DR alleles.
- HLA-DR allele is HLA-DRB 1 *0101 and/or HLA-DRB 1 *0401.
- the subject is at risk for, or is suspected of having, rheumatoid arthritis.
- the method further comprises the step of treating the subject with one or more of a nonsteroidal anti -inflammatory drug (NSAIDs), a steroid, a disease modifying anti-rheumatic drug (DMARD), and a biologic.
- NSAIDs nonsteroidal anti -inflammatory drug
- DMARD disease modifying anti-rheumatic drug
- kits comprising one or more potential antigen and/or potential epitope of filamin-A and/or N-acetylglucosamine-6-sulfatase, and reagents for conducting an assay for detecting the presence of an antibody in a sample that binds to the one or more potential antigen and/or potential epitope of the filamin-A and N-acetylglucosamine-6-sulfatase.
- the potential antigen and/or potential epitope of filamin-A comprises the amino acid sequence NPAEFVVNTSNAGAG (SEQ ID NO: 1) or an antigenic portion thereof, in one embodiment, the potential antigen and/or potential epitope of N-acetylglucosamine-6-sulfatase comprises the amino acid sequence FEPFFMMIATPAPH (SEQ ID NO: 2) or an antigenic portion thereof.
- the assay is an enzyme-linked immunosorbent assay (ELISA). In one embodiment, the assay is a western blot.
- ELISA enzyme-linked immunosorbent assay
- Another aspect of the invention relates to a kit or method disclosed above for use in identifying a subject with rheumatoid arthritis.
- diagnosis refers to determining the nature or the identity of a condition or disease or disorder, detecting and/or classifying the disease and/or disorder in a subject.
- a diagnosis may be accompanied by a determination as to the severity of the disease.
- the term also encompasses assessing or evaluating the disease status (progression, regression, stabilization, response to treatment, etc.) in a patient known to have the disease).
- Diagnosis as it relates to the present invention, relates to the diagnosis of chronic inflammatory arthritis e.g., Rheumatoid arthritis.
- the diagnosis can be differential diagnosis.
- differential diagnosis refers to determine the nature or the identity of a condition or disease or disorder, detecting and/or classifying the disease and/or disorder in a subject.
- a diagnosis may be accompanied by a determination as to the severity of the disease.
- the term also encompasses assessing or evaluating the disease status (progression, regression, stabilization, response to treatment, etc.) in a patient known to have the disease).
- biological sample refers to a sample obtained for evaluation in vitro.
- the biological sample can be any sample that is expected to contain antibodies and/or immune cells.
- the sample can be taken from a part of the body that is specifically affected by the disorder, such as taken specifically from a site of inflammation or pathology in the subject (e.g., synnovial fluid, synovial tissue, synovial fluid mononuclear cells (SFMC), spinal fluid, etc.) or can be a more systemic sample (e.g., peripheral blood, peripheral blood mononuclear cells (PBMC), whole blood or whole blood pre-treated with an anticoagulent such as heparin, ethylenediamine tetraacetic acid, plasma or serum).
- PBMC peripheral blood mononuclear cells
- Sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous liquids, or the like; methods of treatment can also involve separation, filtration, distillation, concentration, inactivation of interfering components, and the addition of reagents.
- immunologically reactive or “immunoreactive” is defined as the capability of the molecule (e.g., whole protein or polypeptide fragments thereof) of the present invention to induce a specific immune response (e.g. T cell reactivity, B cell response) in appropriate subjects or cells and to bind with specific antibodies.
- a specific immune response e.g. T cell reactivity, B cell response
- the immunological reactivity can be assayed in a biological sample comprising immunological cells and/or antibodies obtained from a subject by methods described herein.
- autoantigen/self-antigen is any substance normally found within a subject which, in an abnormal situation, is no longer recognized as part of the subject itself by the lymphocytes or antibodies of that subject, and is therefore attacked by the immune system as though it were a foreign substance.
- An autoantigen can be a naturally occurring molecule such as a protein (e.g., GNS, filamin A) normally produced and used by the subject itself, eliciting an immune response possibly leading to an autoimune disease (e.g. RA) in the subject.
- antibody refers to an immunoglobulin molecule which is able to "specifically recognize” and/or “specifically bind” to a specific epitope on an antigen.
- Antibodies can be intact immunoglobulins derived from natural sources or from recombinant sources and can be
- Antibodies are typically immunoglobulin molecules.
- autoantibody means an antibody produced by the immune system of a subject that is directed to, and specifically binds to an "autoantigen/self-antigen” or an "antigenic epitope” thereof.
- epitope refers to that portion of any molecule capable of being recognized by, and bound by, a T cell or an antibody (the corresponding antibody binding region may be referred to as a paratope), and/or eliciting an immune response.
- epitopes consist of chemically active surface groupings of molecules, e.g., amino acids, and have specific three-dimensional structural characteristics as well as specific charge characteristics.
- immunogenic epitope as determined by any method known in the art, is defined as a portion of a polypeptide that causes an immune response in a subject.
- antigenic epitope as determined by any methods well known in the art, in that a given antibody or T cell receptor specifically recognizes and specifically binds to a given antigen. It can be, and is defined as a portion of a protein (e.g. GNS, filamin A). As used herein, “antigenic portion” refers to the portion of GNS and filamin A that includes the antigenic epitopes.
- bind and/or “specifically recognize” refers to the higher affinity of a binding molecule for a target molecule compared to the binding molecule's affinity for non-target molecules.
- a binding molecule that specifically binds a target molecule does not substantially recognize or bind non-target molecules, e.g., an antibody "specifically binds” and/or “specifically recognize” another molecule, meaning that this interaction is dependent on the presence of the binding specificity of the molecule structure, e.g., an antigenic epitope.
- an antibody that specifically binds to the antigenic epitope of protein molecules such as GNS, filamin A, and/or polypeptide fragments thereof, instead of indiscriminately binding to cause non-specific binding and/or background binding.
- non-specific binding and background binding refers to the interaction that does not depend on the presence of specific structure (e.g., a specific antigenic epitopes).
- an "immunoassay” refers to any binding assay that uses an antibody capable of binding specifically to a target molecule to detect and quantify the target molecule.
- an "appropriate control” refers to one or more biological samples obtained from a subject not afflicted with a disease or disorder that features abnormal level of the molecule and measurement of the molecule therein.
- An example of an appropriate control can be biological sample from a subject not afflicted from RA.
- an appropriate negative control sample would not be positive for T cell reactivity to and/or show presence of autoantibodies to GNS, filamin A and/or polypeptide fragments thereof when tested using the methods described herein.
- disease refers to any alternation in state of the body or of some of the organs, interrupting or disturbing the performance of the functions and/or causing symptoms such as discomfort, dysfunction, distress, or even death to the person afflicted or those in contact with a person.
- a disease or disorder can also be related to a distemper, ailing, ailment, malady, disorder, sickness, illness, complaint, or affectation.
- the terms “treat,” “treatment,” “treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of chronic inflammatory arthritis, (e.g., Rheumatoid arthritis), an associated condition and/or a symptom thereof.
- the term “treating” includes reducing or alleviating at least one adverse effect or symptom of RA.
- Treatment is generally "effective” if one or more symptoms or clinical markers (e.g. antibodies to one or more of GNS, filamin A or cyclic citrullinated peptide (anti-CCP) and/or rheumatoid factors) are reduced.
- treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of, or at least slowing of, progress or worsening of symptoms compared to what would be expected in the absence of treatment. Accordingly in case of chronic inflammatory arthritis such as RA, “effective treatment” can for example reduce inflammation, swelling and joint pain, bone deformity and/or result in reduction in T or B cell reactivity to GNS, filamin A and/or polypeptides thereof and/or reduction in autoantibodies to GNS, filamin A and/or polypeptides thereof compred to that observed pre -treatment, as determined by methods described herein.
- Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, remission (whether partial or total), and/or decreased mortality.
- treatment is considered effective if the condition is stabilized.
- treatment also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).
- a "subject”, “patient”, “individual” and like terms are used interchangeably and refers to a vertebrate, preferably a mammal, more preferably a primate, still more preferably a human.
- Mammals include, without limitation, humans, primates, rodents, wild or domesticated animals, including feral animals, farm animals, sport animals, and pets.
- Primates include, for example, chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus.
- Rodents include, for example, mice, rats, woodchucks, ferrets, rabbits and hamsters.
- Domestic and game animals include, for example, cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, and canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.
- feline species e.g., domestic cat
- canine species e.g., dog, fox, wolf
- avian species e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.
- the terms, "individual,” “patient” and “subject” are used interchangeably herein. In one embodiment the subject is male. In another embodiment, the subject is female.
- the subject is a mammal.
- the mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples.
- Mammals other than humans can be advantageously used as subjects that represent animal models of conditions or disorders associated with RA. Such models are known in the art and are described in (71).
- the compositions and methods described herein can be used to diagnose domesticated animals and/or pets.
- a subject can be one who has been previously diagnosed with or identified as suffering from or under medical supervision for a chronic inflammatory and/or autoimmune disease (e.g., RA).
- a subject can be one who is diagnosed and currently being treated for, or seeking treatment, monitoring, adjustment or modification of an existing therapeutic treatment, or is at a risk of developing RA, e.g., due to family history, carrying alleles or genotype associated with RA (e.g. HLA-DRB 1 *0101 and DRB 1 *0401, HLA- DRB 1 *0405 and DRB 1 *0408).
- the subject can exhibit one or more symptoms of autoimmune disease (e.g., RA) (e.g. swollen joints, joint pains).
- the subject may have tested positive with other assays for RA associated factor.
- factors include rheumatoid factor, anti-citrullinated protein antibodies (ACPA), one or more of HLA-DR alleles associated with RA, or other autoantigens.
- the subject may lack one or more symptoms of autoimmune disease.
- the subject may be identified as testing negative for other RA associated factors (rheumatoid factor, anti-citrullinated protein antibodies (ACPA), one or more of HLA-DR alleles, and other autoantigens).
- protein As used herein, the terms “protein”, “peptide” and “polypeptide” are used interchangeably to designate a series of amino acid residues connected to each other by bonds between the alpha-amino and carboxy groups of adjacent residues.
- the terms “protein”, “peptide” and “polypeptide” refer to a polymer of amino acids, including modified amino acids (e.g.,, phosphorylated, glycated, glycosylated, etc.) and amino acid analogs, regardless of its size or function.
- modified amino acids e.g., phosphorylated, glycated, glycosylated, etc.
- amino acid analogs regardless of its size or function.
- Protein and “polypeptide” are often used in reference to relatively large polypeptides, whereas the term “peptide” is often used in reference to small polypeptides, but usage of these terms in the art overlaps.
- the terms “protein”, “peptide” and “polypeptide” are used interchangeably herein when
- statically significant or “significantly” refers to statistical significance and generally means a difference of two standard deviations (2SD) or more.
- FIGs. 1A-1D show degree of overlap in HLA-DR-presented peptides and their source proteins identified in the synovial tissue (ST), synovial fluid mononuclear cells (SFMC) or peripheral blood mononuclear cells (PBMC) of RA or Lyme arthritis (LA) patients.
- the Venn diagrams depict the number of shared peptides or source proteins identified in the ST, SFMC or PBMC of individual RA or LA patients or in the entire RA and/or LA cohort.
- FIG. 1A Shared peptides or
- FIG. IB shared source proteins identified in patients RA2 or LA5.
- FIG. 1C Shared peptides or (FIG.
- FIGs. 2A-2B show high abundance, high accuracy peptide fragment ions can provide full sequence coverage and clearly distinguish asparagine deamidation from arginine citrullination.
- FIG. 2A CID MS2 spectrum, recorded using the ion trap on the LTQ-Orbitrap XL MS for analysis of the mixture of MHC class Il-presented peptides recovered from the synovial tissue of patient RA3. The spectrum was assigned to a modified form of the peptide 27 VNDTQFVRFDSDAASPRG 44 (SEQ ID NO: 5) derived from the source protein B6V6K3 MHC class I antigen (fragment).
- FIGs. 3A-3F show Tandem mass spectra for HLA-DR-presented peptides identified to be immunogenic in patients with RA or LA.
- FIG. 3A 40 LGRFERMLAAQGVDPG 355 (SEQ ID NO: 6) from endothelial cell growth factor was identified by OMSSA from LAI ST (22).
- FIG. 3B 40 LGRFERMLAAQGVDPG 355 (SEQ ID NO: 6) from endothelial cell growth factor was identified by OMSSA from LAI ST (22).
- FIG. 6 55 IEGNLIFDPNNYLPK 669 (SEQ ID NO: 7) from apolipoprotein B-100 was consistently identified by Mascot and X!Tandem from LA5 ST (23).
- FIG. 3C 208 GTNLFLVAAHELGHS 222 (SEQ ID NO: 8) from matrix metalloproteinase-10 (stromelysin 2) was identified by Mascot from LA4 ST (24)
- FIG. 3D 285 DKVLIRIMVSRSEVD 299 (SEQ ID NO: 9) from annexin A2 was consistently identified by Mascot, OMSSA, and X!Tandem from RA1 ST (25).
- FIG. 3C 208 GTNLFLVAAHELGHS 222 (SEQ ID NO: 8) from matrix metalloproteinase-10 (stromelysin 2) was identified by Mascot from LA4 ST (24)
- FIG. 3D 285 DKVLIRIMVSRSEVD 299 (SEQ ID NO: 9) from annex
- NPAEFVVNTSNAGAG 2460 (SEQ ID NO: 1) from filamin A was consistently identified by Mascot, OMSSA, and X! Tandem from RA2 ST (the same peptide was also identified consistently by Mascot, OMSSA, and X! Tandem from RA2 PB) (26) and (FIG. 3F) 222 FEPFFMMIATPAPH 235 (SEQ ID NO: 2) from N-acetylglucosamine-6-sulfatase was consistently identified by Mascot, OMSSA, and X!Tandem from RA2 ST (26) Note: ° loss of H20; * loss of NH3.
- FIG. 4 shows clinical characteristics, number of HLA-DR-presented peptides and source proteins identified from the case patient RA2. lof 89 HLA-DR presented peptides identified from synovial tissue and 1 of 15 HLA-DR presented peptides identified from her peripheral blood of patient induced the patient's PBMC to secrete IFNy. These reactive peptides were derived from the proteins GNS and filamin A respectively.
- FIGs. 5A-5B are plots showing T and B cell autoreactivity to Filamin A.
- FIG. 5A PBMC from healthy control (HC) subjects or RA patients were tested for T cell autoroactivlty against the filamin A peptide, plus three additional filamin A peptides predicted to be promiscuous HLA-DR binders (promiscuous T cell epitopes).
- Each assay also included a positive control (PHA) and a negative control (no peptides), T cell reactivity was measured using an IFNy enzyme linked immunospot (ELISpot) assay.
- ELISpot enzyme linked immunospot
- FIG. 5B The levels of IgG anti-filamin A in the sera of HC subjects, RA patients or Lyme arthritis (LA) patients were measured by enzyme-linked immunosorbent assay (ELISA). Plates were coated with recombinant human Filamin A and the wells were incubated with serum samples from each test subject. As controls, wells were also incubated with recombinant IgG anti-filamin A (positive control) or buffer (negative control). Bound IgG anti-filamin antibodies were detected using horseradish peroxidase- conjugated goat anti-human IgG followed by TMB substrate.
- ELISA enzyme-linked immunosorbent assay
- the shaded gray area corresponds to 3 standard deviations above the mean of HC subjects. Pecrcentage of positive response for each patient group are ashown below the graph. P values were calculated using an inpaired t-test. Horizontal line indicates the mean of each dataset. The method used to identify this disease associated autoantigen is described in references (22, 30).
- FIGs. 6A-6B are plots showing T and B cell autoreactivity to N-acetylglucosamine-6-sulfatase.
- FIG. 6A PBMC from healthy control (HC) subjects or RA patients were tested for T cell autoroactivlty against the GNS peptide identified from the synovial tissue of patient with RA, plus three additional GNS peptides predicted to be promiscuous HLA-DR binders (promiscuous T cell epitopes).
- Each assay also included a positive control (PHA) and a negative control (no peptides), T cell reactivity was measured using an IFNy enzyme linked immunospot (ELISpot) assay.
- PHA positive control
- no peptides no peptides
- the spot forming units (SFU) per 10 5 were calculated. A positive response was defined as 3 standard deviations above the mean SFU/10 6 cells of healthy control subjects (area above the gray shaded region).
- FIG. 6B The levels of IgG anti-GNS in the sera of HC subjects, RA patients or Lyme arthritis (LA) patients were measured by enzyme-linked immunosorbent assay (ELISA). Plates were coated with recombinant human GNS and the wells were incubated with serum samples from each test subject. As controls, wells were also incubated with recombinant IgG anti-GNS (positive control) or buffer (negative control).
- Bound IgG anti-GNS antibodies were detected using horseradish peroxidase -conjugated goat anti-human IgG followed by TMB substrate.
- the shaded gray area corresponds to 3 standard deviations above the mean of HC subjects.
- Pecrcentage of positive response for each patient group are ashown below the graph.
- P values were calculated using an inpaired t-test. Horizontal line indicates the mean of each dataset. The method used to identify this disease associated autoantigen is described in references (22, 30).
- FIG. 7 shows serum levels of GNS protein determined by sandwich ELISA. Positivity was calculated as >3SD above the mean of normal control (area above the shaded region). HC, healthy control; SLE, systemic lupus; Other A, psoriatic arthritis, ankylosing spondylitis, osteoarthritis; LA, Lyme arthritis; RA, rheumatoid arthritis. 13% of RA patients had high serum GNS protein levels.
- FIG. 8 shows serum levels of filamin A protein determined by sandwich ELISA. Positivity was calculated as >3SD above the mean of normal control (area above the shaded region). HC, healthy control; SLE, systemic lupus; Other A, psoriatic arthritis, ankylosing spondylitis, osteoarthritis; LA, Lyme arthritis; RA, rheumatoid arthritis. 24% of RA patients had high serum filamin A protein levels.
- FIG. 9 shows the amino acid sequence of human GNS (Genbank Accession No. NP_002067.1) (SEQ ID NO: 3).
- FIG. 10 shows the amino acid sequence of human filamin A (See Genbank Accession No. NP_001104026.1) (SEQ ID NO: 4).
- N-acetylglucosamine-6-sulfatase a lysosomal enzyme
- filamin A an actin-binding protein
- One aspect of the invention relates to a method of diagnosing rheumatoid arthritis in a subject by determining whether the subject demonstrates immunological reactivity to filamin-A and/or N- acetylglucosamine-6-sulfatase. Immunological reactivity of the subject to one or more of filamin-A and N-acetylglucosamine-6-sulfatase, as compared to an appropriate control, indicates the subject has rheumatoid arthritis.
- Immunoreactivity of a subject to the protein is determined, for example, by obtaining a biological sample from the subject containing antibodies or immune cells (e.g., T cells), and then assaying that biological sample for autoantigen immunoreactivity.
- Immunoreactivity to a molecule e.g, a protein
- the immunological reactivity demonstrated by the subject can be T cell reactivity or B cell reactivity (e.g., has antibodies that specifically bind to the filamin-A and/or N-acetylglucosamine-6- sulfatase).
- T cell and B cell reactivity of a subject can be determined by various methods known in the art.
- T cell reactivity is performed with an antigenic fragment of the full length molecule.
- B cell reactivity can be determined using a full length protein, however in some embodiment, shorter fragments may be used. Any method known in the art can be used to identify the immunological reactivity.
- One aspect of the invention relates to a method for diagnosing rheumatoid arthritis in a subject by identifying the presence of antibodies in the subject that specifically bind to the filamin-A and/or N- acetylglucosamine-6-sulfatase protein or polypeptide fragment thereof.
- the assay involves contacting a biological sample obtained from the subject with the full length protein or representative fragments thereof (referred to as the test antigen), under conditions that allow an immunocomplex of the antibody and the polypeptide to form, and then assaying for the presence of the immunocomplex.
- ELISA ELISA
- agglutination test direct immunofluorescence assay
- indirect immunofluorescence assay indirect immunofluorescence assay
- radioimmunoassay radioimmunoassay
- immunoblot assay A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein, (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
- the assay involves a detectable label that is used to facilitate detection of the complex through detection of the label.
- a negative control is the same type of biological sample obtained, for example, from a healthy subject.
- a negative control is performed with the same sample of the subject, using a protein to which the subject has no immunoreactivity.
- Reactivity that indicates detection of a significant level of the antibody complex above background indicates a positive result.
- reactivity is identified by detection of the label.
- a determination of reactivity that is >3 standard deviations (SD) above the mean of a sample of a control is considered a positive result.
- SD standard deviations
- a result that is at least 2-fold above background is indicative of positive.
- higher levels of detection are used to indicate a positive result (e.g., at least 3-fold, 4-fold, or 5-fold above background).
- One aspect of the invention relates to a method for diagnosing rheumatoid arthritis in a subject by identifying the presence of T cells in the subject that are specifically reactive to GNS and/or filamin A. This is typically accomplished by obtaining a biological sample from the subject that contains T cells, and exposing the cells in the biological sample to one or more polypeptide fragments of filamin-A and/or N- acetylglucosamine-6-sulfatase (also referred to as the test fragment), and assaying for a response to the test fragment such as stimulation or proliferation.
- peripheral blood mononuclear cells (PBMC) or synovial fluid mononuclear cells (SFMC) of the subject are contacted with the test antigen in vitro under conditions conducive to stimulation.
- the cells are then monitored for a response that indicates stimulation.
- T cell proliferation in vitro or cytokine production e.g., IFN- ⁇
- Identification of a response e.g,. T cell proliferation or cytokine secretion substantially over that of an appropriate control sample indicates stimulation has occurred.
- the level of one or more cytokines that are indicative of T cell activation can be monitored in the supernatant of the cells as an indication of T cell activation.
- One such cytokine is IFN- ⁇ .
- Other cytokines to monitor include, without limitation IL-17, IL-12, and IL-10.
- the levels of one or more of such cytokines can be monitored. A significant increase in IFN- ⁇ , IL-17, and/or IL-12, and/or a significant decrease in IL-10 levels indicates activation.
- Detection of the stimulation indicates that the sample comprises immunological cells that are immunologically reactive to the test antigen, which in turn indicates that the subject from whom the sample was obtained is immunologically reactive to the test antigen.
- a positive assay result indicates that the test antigen is an autoantigen in the subject, and that the subject has rheumatoid arthritis.
- Typical assays for use in this method are T cell proliferation assays, such as H-thymdine incorporation assay, CFSE dilution, or an ELISPOT, and also T cell reactivity assays. Methods of determining T cell reactivity are well known in the art and are described in for example US5750356A.
- Reactivity that indicates a detection of a significant level of stimulation above background is expected to serve as a positive result.
- a determination of stimulation that is ⁇ 3 standard deviations (SD) above the mean of a sample of a healthy control subject is considered a positive result.
- a result that is at least 2-fold above background is indicative of positive.
- higher levels of stimulation is used to indicate a positive result (e.g., at least 3-fold, 4-fold, or 5 -fold above background).
- Test antigen for use in the methods herein described include, without limitation, full length GNS, filamin A, and/or polypeptide fragments thereof.
- GNS is a lysosomal enzyme, involved in the catabolism of heparin, heparan sulphate, and keratan sulphate.
- the GNS of the methods and kits disclosed herein can be full length GNS protein, a polypeptide fragment thereof, a derivative thereof or an antigenic portion thereof.
- the GNS polypeptide can be mammalian GNS.
- the GNS can also be an isoform of the full length GNS or a polypeptide fragment thereof.
- the GNS of the methods and kits disclosed herein can be derived from human GNS having the amino acid sequence shown in FIG. 9 (SEQ ID NO: 3). (See Genbank Accession No. NP_002067.1, which is incorporated herein in its entirety).
- the GNS of the methods and kits described herein can be a polypeptide fragment including or derived from human full length GNS having the amino acid sequence of SEQ ID NO: 3.
- the polypeptide fragment refers to fragment of the full length GNS of at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 or more consecutive amino acids of SEQ ID NO:3, that has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of GNS of SEQ ID NO: 3.
- the polypeptide fragment comprises the amino acid
- the immunological reactivity can be determined by T cell reactivity or B cell response to GNS and can be assayed by the skilled practioner by the assays described herein.
- assays for T cell reactivity include, without limitation, measurement of in vitro T cell proliferation, measurement of in vitro IFN- ⁇ secretion, induced in PBMC or SFMC of the subject in response to GNS.
- assays for B cell responses include, without limitation, detection and/or measurement of autoantibodies in a biological sample that specifically recognize and/or specifically bind to GNS.
- the GNS or fragment thereof used can be human GNS.
- the polypeptide and encoding nucleic acid sequences of GNS and of other isoforms of human origin and those of a number of animals are publically available, e.g., from the NCBI website.
- the GNS or fragment thereof used can be a mammalian homolog of human GNS or a polypeptide fragment thereof.
- the GNS polypeptide has an amino acid sequence at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence of SEQ ID NO: 3 and has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of GNS of SEQ ID NO: 3.
- the GNS polypeptide has an amino acid sequence that has at least 85%, at least 90%, at least 95%, at least 97% or at least 99% amino acid sequence homology to amino acid sequence of SEQ ID NO: 3 and has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of GNS of SEQ ID NO: 3.
- the GNS is a polypeptide fragment of SEQ ID NO: 3 of at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 consecutive amino acids of SEQ ID NO: 3, that has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of GNS of SEQ ID NO: 3.
- Percent (%) amino acid sequence identity for a given polypeptide sequence relative to a reference sequence is defined as the percentage of identical amino acid residues identified after aligning the two sequences and introducing gaps if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.
- Percent (%) amino acid sequence homology for a given polypeptide sequence relative to a reference sequence is defined as the percentage of identical or strongly similar amino acid residues identified after aligning the two sequences and introducing gaps if necessary, to achieve the maximum percent homology.
- Non identities of amino acid sequences include conservative substitutions, deletions or additions that do not affect immunological reactivity of GNS or filamin a. Strongly similar amino acids can include, for example, conservative substitutions known in the art.
- Percent identity and/or homology can be calculated using alignment methods known in the art, for instance alignment of the sequences can be conducted using publicly available software software such as BLAST, Align, ClustalW2. Those skilled in the art can determine the appropriate parameters for alignment, but the default parameters for BLAST are specifically contemplated.
- Filamin A, alpha is an actin-binding protein that crosslinks actin filaments and links actin filaments to membrane glycoproteins.
- the encoded protein is involved in remodeling the cytoskeleton to effect changes in cell shape and migration. This protein interacts with integrins, transmembrane receptor complexes, and second messengers.
- the filamin A of the methods and kits disclosed herein can be full length filamin A protein, a polypeptide fragment thereof, a derivative thereof or an antigenic portion thereof.
- the filamin A or fragment thereof used can be human filamin A.
- the filamin A polypeptide can be mammalian filamin A.
- the filamin A can also be an isoform of the full length filamin A or a polypeptide fragment thereof.
- the filamin A of the methods and kits disclosed herein can be derived from human filamin A having the amino acid sequence shown in FIG. 10 (SEQ ID NO: 4). See Genbank Accession No. NP_001104026.1, which is incorporated herein in its entirety).
- the filamin A of the methods and kits described herein can be a polypeptide fragment including or derived from human full length filamin A having the amino acid sequence of SEQ ID NO: 4.
- the polypeptide fragment refers to fragment of the full length filamin A of at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 consecutive amino acids of SEQ ID NO: 4, that has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of filamin A of SEQ ID NO: 4.
- the polypeptide fragment comprises the amino acid sequence, NPAEFVVNTSNAGAG (SEQ ID NO: 1).
- the immunological reactivity can be determined by T cell reactivity or B cell response to filamin A by the skilled practioner by assays known in the art, some of which are described herein. Examples of assays for T cell reactivity include, without limitation, measurement of in vitro T cell proliferation, measurement of in vitro IFN- ⁇ secretion, induced in PBMC or SFMC of the subject in response to filamin A (e.g., using an immunogenic polypeptide fragment).
- Example of assays for B cell responses include, without limitation, detection and/or measurement of autoantibodies in a biological sample that specifically recognize and/or specifically bind to filamin A.
- Examples of assays for T cell reactivity include, without limitation, measurement of T cell proliferation and IFN- ⁇ secretion by PBMC or SFMC of the subject by filamin A in vitro.
- human filamin A or a polypeptide fragment thereof is used.
- the polypeptide and coding nucleic acid sequences of filamin A and of other isoforms of human origin and those of a number of animals are publically available, e.g., from the NCBI website and are well known in the art.
- the filamin A of the methods and kits described herein is a mammalian homolog of human filamin A or a polypeptide fragment thereof.
- the filamin A polypeptide has an amino acid sequence at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence of SEQ ID NO: 4 and has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of filamin A of SEQ ID NO: 4.
- the filamin A polypeptide has an amino acid sequence that has at least 85%, at least 90%, at least 95%, at least 97% or at least 99% amino acid sequence homology to amino acid sequence of SEQ ID NO: 4 and has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of filamin A of SEQ ID NO:4.
- the filamin A is a functional fragment of SEQ ID NO: 4 of at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 consecutive amino acids of SEQ ID NO: 4, that has at least about 70%, 80%, 90%, 100% or more than 100% of the immunological reactivity of filamin A of SEQ ID NO: 4.
- the entire full length protein or protein fragments can be used in the assays described herein. Combinations of full length protein and protein fragments can also be used, as can combinations of proteins/fragments that represent the different autoantigens (e.g., testing for one or more of GNS and filamin A reactivity in the same assay, or side by side in the same patient).
- the appropriate polypeptide or fragment thereof for use in the specific method can be determined by the skilled practioner.
- the proteins or fragments can be can be recombinant, purified, isolated, naturally occurring or synthetically produced.
- nucleic acid, protein, cell or a vector indicates that the nucleic acid, protein, vector or cell containing them have been modified by introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or a protein, or that the cell is derived from a cell so modified.
- heterologous refers to the fact that often the transferred protein was initially derived from a different cell type or a different species from the recipient. Typically the protein itself is not transferred, but instead the genetic material coding for the protein (often the complementary DNA or cDNA) is added to the recipient cell.
- Either the full length protein, or protein fragments derived from the full length protein can be used to identify immunoreactivity in a subject to the proteins disclosed herein.
- the specific molecules used in the assays described herein e.g., full length protein(s), representative fragments thereof, or a combination of the full length and fragments
- test antigen e.g., full length protein(s), representative fragments thereof, or a combination of the full length and fragments
- fragments of a full length protein to use in the assay can be determined by the skilled practitioner. Typically, a cocktail of fragments derived from the same protein are used for determination of reactivity of a subject to that protein. Depending upon the length, the number of different protein fragments can be determined and optimized by the skilled practitioner. In one embodiment, 2 or more protein fragments are used. In one embodiment, 3 or more, 4, 5, 6, 7, 8, 9, or 10 or more protein fragments are used. In one embodiment, a protein fragment is at least 8 amino acids in length (e.g., > 8, > 9, > 10, > 11, > 12, > 13, >14, > 15 amino acids).
- Specific protein fragments can be identified for use in the herein described methods such as those predicted for presentation by HLA-DR. Such protein fragment can be identified by the methods described in the examples and also by a variety of software programs available to the skilled practitioner (Lin et al. BMC Immunology 2008, 9: 8). In one embodiment, TEPITOPE 2000 (Sturniolo et al. 1999 Nature Biotechnology. 17; 555-561) is used. Other freely accessible online programs offered by the Immune Epitope Database and Analysis Resource (http://www.iedb.org/) are also available.
- Examples of specific protein fragments of filamin A include, without limitation
- NPAEFVVNTSNAGAG (SEQ ID NO: 1).
- Examples of specific protein fragments of GNS include, without limitation
- Reactivity to one or both of GNS and filamin A can be assayed in a single subject. In one embodiment, reactivity to both GNS and filamin A are assayed in a subject. In one embodiment, reactivity in a subject to other suspected autoantigens is also performed in combination with the herein described assays.
- One such autoantigen is cyclic citrullinated peptide (CCP).
- CCP cyclic citrullinated peptide
- ACPAs anti-citrullinated protein antibody
- MCV-assay mutated citrullinated Vimentin
- CCP-assay mutated citrullinated peptides
- V CP -assay viral citrullinated peptides
- Non limiting examples include WO 2005/085858 discloses a method of assessing RA by measuring CCP and serum amyloid A (SAA).
- SAA serum amyloid A
- WO 2005/064307 and US 2007/0264673 assess RA by measuring CCP and IL-6.
- WO 2005/029091 and US 2006/094056 provide methods to diagnose, treat, or evaluate inflammatory/autoimmune diseases such as RA by sampling fluids from a human with a suspected diagnosis by detecting CCP.
- US 2007/0148704 and WO 2007/039280 disclose use of CCP and antibodies as biomarkers in diagnosing RA.
- WO 2006/008183 discloses various biomarkers for RA.
- a subject suspected of having rheumatoid arthritis can be tested by the methods described herein.
- the subject may exhibit one or more symptoms of rheumatoid arthritis prior to performance of the methods.
- Rheumatoid arthritis is an autoimmune disease that causes the body's immune system to attack joint tissues, which leads to inflammation of joint lining. Inflammation of the joints is the primary manifestation of RA.
- Early symptoms of RA include affected joints being swollen, tender, warm, painful and stiff especially in the morning. Morning stiffness may last for at least an hour. The pain associated with RA is induced at the site of inflammation.
- Non limiting examples of other symptoms for RA include presence of rheumatoid nodules in the skin, fatigue, joint deformity and reduction in range of motion of affected joints, dryness of eyes and mouth.
- Early symptoms associated with RA are also seen in patients with other autoimmune related diseases such as lupus, or in other forms of arthritis, such as osteoarthritis, or in the pain syndrome, fibromyalgia.
- the subject exhibits symptoms of RA and/or other autoimmune related disease manifestation known in the art e.g., Tenosynovitis, osteoporosis, carpal tunnel syndrome.
- the diagnostic methods of RA includes X-ray, MRI and/or ultrasound imaging of the affected joints and blood/serological tests.
- blood/serology tests known in the art to be conducted for diagnosis of RA include measurements of ; Erythrocyte Sedimentation Rate (ESR), Rheumatoid factor (RF), Anti-cyclic Citrullinated Peptide (anti-CCP), Antinuclear Antibody (ANA), Uric Acid, complete blood count: measures the numbers of red and white cells in your blood, C-reactive protein (CRP).
- ESR Erythrocyte Sedimentation Rate
- RF Rheumatoid factor
- anti-CCP Anti-cyclic Citrullinated Peptide
- ANA Antinuclear Antibody
- Uric Acid complete blood count: measures the numbers of red and white cells in your blood, C-reactive protein (CRP).
- CRP C-reactive protein
- the subject has been or is further tested for one or more of rheumatoid factor (RF), anti -citrullinated protein antibodies (ACPA), and one or more of HLA-DR alleles.
- RF rheumatoid factor
- ACPA anti -citrullinated protein antibodies
- HLA-DR alleles include HLA- DRB 1*0101, HLA-DRB 1*0401.
- identification of immunoreactivity to one or more of the proteins described herein can be used in diagnosis of RA.
- the methods disclosed herein can be used to identify a patient with RA.
- the methods disclosed herein can be used for differential diagnosis of RA. Immunoreactivity of a subject to one or more of the proteins can determined in vitro using suitable biological samples disclosed herein by a variety of methods available to the skilled practitioner.
- reactivity to GNS and filamin A can be used as a biomarker for the diagnosis of a condition (e.g., RA and associated symptoms). More specifically, subject immunoreactivity (e.g., autoantigen reactive T cells, and/or anti-autoantigen antibodies) is indicative of the condition.
- subject immunoreactivity e.g., autoantigen reactive T cells, and/or anti-autoantigen antibodies
- another aspect of the invention relates to a method of diagnosing the condition in a subject (e.g., RA) by determining whether the subject is immunologically reactive with one or more of GNS or filamin A by the herein described methods.
- the determination may be made in conjunction with the presence of other such symptoms of the condition present in the subject, for example, arthritic symptoms in a subject, or neurologic symptoms in a subject, or cardiac symptoms in a subject.
- the determination of immunological reactivity of a subject indicates the subject has, or is likely to develop, the condition.
- the condition can be further confirmed by the determination of immunological reactivity to additional proteins such as antibodies to citrullinated proteins (ACPA), antinuclear antibody (ANA), anti-neutrophil cytoplasmic antibodies (ANCA) and presence of rheumatoid factors and other diagnostic tests known to those skilled in the art and described above.
- ACPA citrullinated proteins
- ANA antinuclear antibody
- ANCA anti-neutrophil cytoplasmic antibodies
- Various assays can be used to identify antibodies present in a serum sample that bind the test antigen (e.g., ELISA, agglutination test, direct immunofluorescence assay, indirect immunofluorescence assay, western blot, an immunoblot assay).
- the assay could be an immunoblot that carries a recombinant test antigen (full length or peptide fragment(s)).
- the methods described herein can also include determination of rheumatoid factor, ACPA and/or ANA.
- the test antigens disclosed herein can be included in or used in conjunction with an assay such as the Sure-Vue® RF (Fishersci), RFscanTM Card Test Kit (BD Biosciences), Anti- Rheumatoid Factor IgM ELISA Kit (abeam), AVITEX® -RF (Omega diagnostics) Citrullinated Protein Antibodies IgG ELISA Kit (Omega diagnostics) Anti-CCP EIA (Bio-Rad), BioPlex® 2200 Anti-CCP (Bio-Rad), CCPoint® (Eurodiagnostica), DIASTAT® anti-nuclear antibody (ANA) test
- Test-antigen reactive T cells in PBMC and SFMC can be assessed using a number of assays.
- reactive T cells in PBMC and SFMC can be assessed using tetramer reagents comprising recombinant HLA-DR molecules and test antigen epitopes.
- the test antigen may comprise naturally occurring or analog or derivative amino acids, as long as the immunoreactive or immunostimulatory nature of the peptide is retained to sufficient degree to allow T cell activation and/or antibody binding.
- some amino acids may be added to or subtracted from the native protein or polypeptide fragments as known in the art.
- some amino acids of the native human protein or polypeptide fragments may be substituted with amino acids that occur in other species, or be substituted as known in the art.
- Amino acid substitution exchange groups and empirical similarities between amino acid residues can be found in standard texts such as Schulz et al., Principles of Protein Structure, 14-16 (Springer-Verlag, New York, 1979).
- test peptide is predicted to be presented by HLA- DR molecules associated with chronic inflammatory arthritis (e.g., RA).
- amino acid substitutions should be made conservatively; i.e., a substitute amino acid should replace an amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.
- the following groups of amino acids represent conservative changes: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile, leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
- Variants within the scope of this invention may also, or alternatively, contain other modifications, including the deletion or addition of amino acids, that have minimal influence on the stimulatory properties, antibody binding, tertiary structure of the peptide.
- conservative substitutions in a protein fragment can be made with the proviso that functional activity is retained to a meaningful degree such that the particular assay (e.g., T cell reactivity or immunoassay) works as intended to provide evidence in diagnosing subjects (e.g., with RA).
- peptides often contain amino acids other than the twenty "naturally occurring" amino acids.
- many amino acids, including the terminal amino acids may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art.
- Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.
- the peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code.
- test antigens contain additional chemical moieties not normally a part of the protein.
- Covalent modifications of the autoantigens are included within the scope of this invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
- derivatization with bifunctional agents is useful for cross-linking the antibody or fragment to a water-insoluble support matrix or to other macromolecular carriers.
- Derivatives also include radioactively labeled peptides that are labeled, for example, with radioactive iodine ( 1251, 1311), carbon (14C), sulfur (35S), tritium (3H) or the like; conjugates of peptides with biotin or avidin, with enzymes, such as horseradish peroxidase, alkaline phosphatase, ⁇ -D- galactosidase, glucose oxidase, glucoamylase, carboxylic acid anhydrase, acetylcholine esterase, lysozyme, malate dehydrogenase or glucose 6-phosphate dehydrogenase; and also conjugates of monoclonal antibodies with biolumine scent agents (such as luciferase), chemoluminescent agents (such as acridine esters), or fluorescent agents (such as phycobiliproteins).
- biolumine scent agents such as luciferase
- Structural analogs of the autoantigens identified herein are provided by known method steps based on the teaching and guidance presented herein.
- Knowledge of the three-dimensional structures of proteins is crucial in understanding how they function.
- the three-dimensional structures of hundreds of proteins are currently available in protein structure databases (in contrast to the thousands of known protein sequences in sequence databases). Analysis of these structures shows that they fall into recognizable classes of motifs. It is thus possible to model a three-dimensional structure of a protein based on the protein's homology to a related protein of known structure. Many examples are known where two proteins that have relatively low sequence homology, can have very similar three dimensional structures or motifs.
- NMR spectroscopic data can combined with computer modeling to arrive at structural analogs of at least portions of the autoantigen (peptides or epitopes) based on a structural understanding of the topography.
- the autoantigen peptides or epitopes
- structural analogs of the autoantigens such as by rationally-based amino acid substitutions allowing the production of peptides in which the binding affinity or avidity is modulated in accordance with the requirements of the expected diagnostic use of the molecule, for example, the achievement of greater binding specificity or affinity.
- the herein described methods may further be used to indicate a therapy for the subject who tests positive.
- the identification of GNS and/or filamin A for a biomarker in RA is an important addition to the clinician's arsenal in combating chronic inflammatory arthritis, and assists the clinician in choosing the course of therapy.
- NSAIDs nonsteroidal antiinflammatory drugs
- steroids e.g., corticosteroid medication such as prednisone
- DMARDs disease modifying anti-rheumatic drugs
- anti- TNF therapy e.g., HUMIRA® (adalimumab), ENBREL® (etanercept)
- HUMIRA® adalimumab
- ENBREL® etanercept
- Other non- limiting examples include Orencia® (abatacept), Kineret® (anakinra), certolizumab® (Cimzia),
- GNS and/or filamin A-specific therapy such as targeting GNS and/or filamin A e.g., GNS and/or filamin A -binding antibodies, may also be beneficial.
- the subject is provided one or more therapies following an indication that they are immunoreactive to an autoantigen.
- another aspect of the invention relate to a method of treating a subject diagnosed with a RA.
- the method comprises diagnosing the subject for the disorder by one or more of the herein described methods, and then treating the subject for said condition. Diagnosis may further include assessing the subject for other symptoms such as a neurological condition or heart condition typically seen with secondary RA symptoms.
- the methods to determine immunoreactivity to autoantigens disclosed herein can be conducted prior to, during and/or after a therapeutic treatment and therefore aid in assessment of effectiveness of the treatment and/or monitor disease progression.
- kits for identifying a subject with a condition such as chronic inflammatory arthritis comprises one or more of GNS, filamin A, or a portion or fragment thereof, such as a set of synthesized peptides, fragments, or epitopes thereof, and reagents necessary for conducting an assay capable of detecting the presence of immunoreactivity of a subject to that test antigen (e.g., an antibody in a sample obtained from said subject that binds to GNS and/or filamin A).
- test antigen e.g., an antibody in a sample obtained from said subject that binds to GNS and/or filamin A
- the kit can be designed for any of the various assays described herein.
- the assay in the kit is an enzyme-linked immunosorbent assay (ELISA) or immunoblot, the components for which are well-known in the art.
- the peptides may be synthesized or obtained from natural or recombinant sources, each of which is well-known in the art.
- the kit may further include other autoantigens known in the art, such as those described herein, (e.g., citrullinated protein/peptides such as citrullinated filaggrin, fibrinogen, fibronectin, a-enolase, collagen type II, histones, vimentin or fragments/epitopes thereof).
- the kit may alternately further comprise buffers, enzymes, and/or containers for performing the reactions or analyses.
- the various reagents within the kit may be provided separately or together as is convenient in a container such as a vial, test tube, flask, bottle or even syringe.
- the components may be suitably aliquotted for performance of the methods.
- the kit may further contain one or more positive and/or negative controls.
- the antigens or other components of the kit may be labeled with a detectable marker.
- the present invention relates to the herein described compositions, methods, and respective component(s) thereof, as essential to the invention, yet open to the inclusion of unspecified elements, essential or not ("comprising).
- other elements to be included in the description of the composition, method or respective component thereof are limited to those that do not materially affect the basic and novel characteristic(s) of the invention ("consisting essentially of). This applies equally to steps within a described method as well as compositions and components therein.
- the inventions, compositions, methods, and respective components thereof, described herein are intended to be exclusive of any element not deemed an essential element to the component, composition or method ("consisting of).
- a method of diagnosing rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with one or more of filamin-A and N-acetylglucosamine-6-sulfatase, wherein immunological reactivity of the subject to one or more of filamin-A and N-acetylglucosamine-6- sulfatase, as compared to an appropriate control, indicates the subject has rheumatoid arthritis.
- determining is by evaluating a biological sample obtained from the subject for immunological reactivity with the one or more of filamin-A and N- acetylglucosamine-6-sulfatase .
- determining immunological reactivity is by detecting the presence of T cells reactive to one or more of filamin-A and N-acetylglucosamine-6- sulfatase, comprising the steps:
- PBMC peripheral blood mononuclear cells
- SFMC synovial fluid mononuclear cells
- step b) is measuring T cell proliferation in vitro, and the subject is identified as having T cell reactive to one or more of filamin-A and N-acetylglucoasmine-6- sulfatase when T cells proliferation is measured as significantly increased over that of an appropriate control.
- step b) is measuring T cell secretion of IFN- ⁇ into cell culture supematants, and the subject is identified as having T cells reactive to one or more of filamin-A and N-acetylglucoasmine-6-sulfatase when secretion of IFN- ⁇ is measured as significantly increased over that of an appropriate control.
- determining immunological reactivity comprises determining if the subject has a B-cell response to one or more of filamin-A and N- acetylglucosamine-6-sulfatase resulting in the production of autoantibodies that specifically recognize the one or more filamin-A and N-acetylglucosamine-6-sulfatase, by contacting the sample with filamin-A protein or a polypeptide fragment thereof and/or N-acetylglucosamine-6-sulfatase protein or a polypeptide fragment thereof, under conditions that allow an immunocomplex of the antibody and the filamin-A or N-acetylglucosamine-6-sulfatase form, and detecting the presence or absence of an immunocomplex, wherein the presence of an immunocomplex indicates the subject presents a B-cell response to filamin-A and/or N-acetylglucosamine-6-sulfatas
- immunocomplex indicates the subject fails to present a B-cell response to filamin-A and/or N- acetylglucosamine-6-sulfatase .
- the assay is an enzyme-linked immunosorbent assay (ELISA), agglutination test, direct immunofluorescence assay, indirect immunofluorescence assay, or an immunoblot assay.
- ELISA enzyme-linked immunosorbent assay
- agglutination test direct immunofluorescence assay
- indirect immunofluorescence assay indirect immunofluorescence assay
- immunoblot assay an enzyme-linked immunosorbent assay
- polypeptide fragment of filamin-A comprises the amino acid sequence NPAEFVVNTSNAGAG (SEQ ID NO: 1) or an antigenic portion thereof.
- polypeptide fragment of N- acetylglucosamine-6-sulfatase comprises the amino acid sequence of FEPFFMMIATPAPH (SEQ ID NO: 2) or an antigenic portion thereof.
- FEPFFMMIATPAPH amino acid sequence of FEPFFMMIATPAPH
- HLA-DR alleles amino acid sequence of FEPFFMMIATPAPH
- NSAIDs nonsteroidal anti-inflammatory drug
- DMARD disease modifying antirheumatic drug
- a kit comprising, one or more potential antigen and/or potential epitope of filamin-A and/or N- acetylglucosamine-6-sulfatase, and reagents for conducting an assay for detecting the presence of an antibody in a sample that binds to the one or more potential antigen and/or potential epitope of the filamin-A and N-acetylglucosamine-6-sulfatase.
- kits of paragraph 14 wherein the potential antigen and/or potential epitope of filamin-A comprises the amino acid sequence NPAEFVVNTSNAGAG (SEQ ID NO: 1) or an antigenic portion thereof.
- kits of paragraph 14 wherein the potential antigen and/or potential epitope of N- acetylglucosamine-6-sulfatase comprises the amino acid sequence FEPFFMMIATPAPH (SEQ ID NO: 2) or an antigenic portion thereof.
- kits of any one of paragraphs 14-16, wherein the assay is an enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- HLA-DR-presented self-peptides were isolated and identified from RA patients' tissue or fluids by tandem mass spectrometry, synthesized and tested for T cell autoreactivity with the matching patient's peripheral blood mononuclear cells (PBMC). Immuno reactive peptides or their source proteins were then tested for T cell autoreactivity by IFN-g ELISpot assay and for autoantibody responses by ELISA using cells and sera from our large cohort of RA patients and control subj ects . All RA patients met the 2010 ACR/EULAR criteria for RA. Results
- HLA-DR-presented peptides identified from her synovial tissue and 1 of 15 HLA-DR-presented peptides identified from her PB induced her PBMC to secrete IFN-g.
- reactive peptides were derived from the proteins N-acetylglucosamine-6-sulfatase (GNS), a lysosomal enzyme, and from filamin A (filamin A), an actin-binding protein, respectively.
- GNS N-acetylglucosamine-6-sulfatase
- filamin A filamin A
- This approach is an effective way to identify novel autoantigens associated with autoimmune forms of arthritis.
- two previously unrecognized autoantigens were identified, each of which is a target of T and B cell responses in about 1/3 of patients with RA, but rarely in those with other types of arthritis.
- HLA-DR-presented peptides could be identified in individual patients - not only from ST, but also from synovial fluid mononuclear cells (SFMC) and peripheral blood mononuclear cells (PBMC), which allow the analysis not only of a greater number of patients, but also of patients seen earlier in the illness.
- SFMC synovial fluid mononuclear cells
- PBMC peripheral blood mononuclear cells
- the increasing sensitivity of new mass spectrometers and improvements in computer programs for spectrum-to-peptide matches resulted in the identification of greater numbers of HLA-DR-presented peptides from each sample.
- 18 new ST, PBMC and SFMC samples were analyzed and previous LC-MS/MS data were re-analyzed to compare with new data from SFMC and PBMC samples.
- T cell epitopes derived from the source proteins endothelial cell growth factor (ECGF) (22) apolipoprotein B-100 (apoB-100) (23), matrix metalloproteinase-10 (MMP- 10) (24) in LA; from annexin A2 in both RA and LA (25) and from N-acetylglucosamine-6-sulfatase and filamin A in RA (26). Furthermore, it was shown that these epitopes or their source proteins were targets of T and B cell responses in many patients (22-26).
- ECGF endothelial cell growth factor
- apoB-100 apolipoprotein B-100
- MMP-10 matrix metalloproteinase-10
- RA2 For one patient (RA2), samples were available from all three sites (ST, SFMC and PBMC), and, for patient RA4, SFMC and PBMC samples (but not ST) were collected at the time of diagnosis, prior to therapy with disease modifying antirheumatic drugs (DMARDs).
- the eight patients with antibiotic-refractory LA included four teenage boys, three adult men and one woman (Table 1).
- Four of the eight patients had the HLA-DR*0101, 0401 or 1501 alleles, which are known to be increased in frequency in patients with refractory LA (58).
- All eight patients were treated with > two months of oral antibiotics, seven also received > one month of IV antibiotics, and seven subsequently received methotrexate.
- the eight patients underwent arthroscopic synovectomies of an affected knee six months to four years after the onset of arthritis, and ST samples were obtained during the surgeries. Additionally, SFMC samples were available from four patients and PBMC from two patients.
- Table 1 Clinical characteristics, number of MS/MS spectra, peptide matches, decoy hits, non-redundant peptides, and source proteins identified from each patient's HLA-DR molecules in synovial tissue, synovial fluid or peripheral blood.
- the lengths of the MHC class II HLA-DR-presented peptides ranged from seven to 27amino acids; the typical length of the peptides was 13-17 amino acids. Altogether, from all three sites, 1,593 non-redundant HLA-DR-presented, self-peptides were identified; these were derived from 870 source proteins.
- the average numbers from patients' SFMC were 51 using the LTQ-Orbitrap XL, 6 using the 6550 Q-TOF, and 70 using the Q Exactive plus MS. From patients' PBMC, the average numbers were 15 using the LTQ- Orbitrap XL, and 50 using the Q Exactive plus MS.
- the sensitivity and data handling capacity of the LC-MS/MS instruments improved during the study, the number of identified HLA-DR-presented peptides steadily increased.
- Table 2 Comparison of the spectra generated and identified by the four different mass spectrometers.
- patient LA5 had a smaller percentage of peptides shared between SFMC and ST (21%) than between PBMC and ST (36%), and the degree of overlap of source proteins between SFMC and ST (16%) was similar between PBMC and ST (22%).
- degree of overlap was compared between pairs of sample types available from the five RA patients or eight LA patients, a similar picture was found.
- more than half of the peptides identified in SFMC were also found in ST (FIG. 1C).
- RA about half of the peptides identified in PBMC were also found in ST
- LA in which many more peptides were identified in ST, only about one-quarter of the PBMC peptides were also found in ST.
- Source Proteins for HLA-DR-presented Peptides The complete lists of consensus peptides were identified by at least two search engines from each site for each patient and the non-redundant HLA- DR-presented peptides and their source proteins were identified as described in methods. The most common source proteins of peptides from ST that were found in at least four patients, regardless of disease, are listed in alphabetical order in Table 3.
- peptides (in order of frequency) were derived from cathepsin S, collagen a-l(I) chain, syntenin-1, serine carboxypeptidase CPVL (probable), albumin, pro-low-density lipoprotein receptor-related protein 1, apolipoprotein A2, complement C3, cytochrome c oxidase subunit 5B (mitochondrial), filamin-A, monocyte differentiation antigen CD14, and stromelysin- 1. Since fewer SFMC and PBMC samples were analyzed, the list from these sites shows the source proteins identified in at least two patients rather than four patients.
- SFMC SFMC
- keratin type II cytoskeletal 1
- nuclease-sensitive element-binding protein 1 Keratin was commonly identified in both SFMC and PBMC. Because of the keratin type and the fact that the samples were not subjected to proteolysis during processing, it is unlikely that these peptides were sample -handling artifacts.
- Table 3 The most abundant source proteins for the identified HLA-DR-presented peptides from three sites in RA and LA patients.
- HLA-DR-presented peptides were derived from source proteins that are thought to serve as potential autoantigens in RA. These included cartilage glycoprotein 39, various types of collagen, enolase, fibrinogen, fibronectin, immunoglobulin, and vimentin (Table 4). Interestingly, HLA-DR-presented peptides from these source proteins were also commonly identified in patients with LA. [00128] Table 4: Source proteins found both in RA and LA that are known or proposed to serve as autoanti ens in RA*
- VNDTQFVRFDSDAASPRG (SEQ ID NO: 5), that corresponds to residues 27 to 44 in the source protein B6V6K3 MHC class I antigen (fragment), which was originally detected in the ST of patient RA3, was assigned as the citrullinated peptide by two protein database search programs during analysis of LC- MS/MS data acquired on the LTQ-Orbitrap XL MS.
- the molecular weight change and partial sequence coverage should not be considered definitive. In this case, the signal for the MS/MS spectrum shown in FIG.
- peptides identified from each patient that correspond to assignments indicated on the MS/MS spectra.
- the peptides found to be immunogenic were derived from the source proteins endothelial cell growth factor (ECGF) (22), apolipoprotein B-100 (apoB-100) (23), matrix metalloproteinase-10 (MMP-10) (24) in LA; from annexin A2 in both RA and LA (25) and from N- acetylglucosamine-6-sulfatase and filamin A in RA (26).
- ECGF endothelial cell growth factor
- apoB-100 apolipoprotein B-100
- MMP-10 matrix metalloproteinase-10
- the immunogenic HLA-DR-presented peptide derived from filamin A was identified in both ST and PBMC, whereas the peptides from ECGF, apoB-100, annexin A2, and N- acetylglucosamine-6- sulfatase were identified only in ST.
- annexin A2 had been previously shown to serve as an autoantigen in several rheumatic diseases, including about 10% of patients with RA (59), it had not been previously identified as an autoantigen in LA (25).
- the isolated peptides have low ionization efficiency and/or are not selected for MS/MS analysis, and not all spectra can be assigned by the search algorithms, due to low signal intensity, incomplete component resolution, and/or the presence of unusual PTMs.
- the performance of MS/MS instruments and search algorithms continues to move forward (60).
- the analyses of SFMC and PBMC each provided a window into the ST repertoire, but also yielded antigenic peptides not found in ST.
- the data herein indicate that a more complete picture in an individual patient can be obtained by analyzing tissue or fluids from more than one site.
- the addition of SFMC and/or PBMC to the analytical scheme has three advantages. First, a more complete picture of an individual patient can be obtained by analyzing samples from multiple sites. Second, since ST can usually only be obtained from patients who undergo surgical procedures, frequently late in the disease, use of SFMC and/or PBMC allows evaluation of patients early in the disease when immune responses may be more robust.
- HLA-DR-presented peptides were identified from many source proteins previously reported to be autoantigens in RA, including vimentin, enolase, fibrinogen and collagen. Interestingly, peptides from many of these same source proteins were frequently found in the joints of LA patients, where they are not known to be immunogenic. In RA, many proteins that contain citrulline have been identified, the non-standard amino acid that results from the enzymatic post-translational modification of arginine, such as vimentin, enolase, fibrinogen, collagen, fibronectin, calreticulin, etc. (11, 61-67).
- ACPA citrullinated proteins
- a disease-linked peptide containing citrulline (neutral R-group) has been shown to have greater affinity for the HLA shared epitope in the P4 pocket, as compared to the unmodified analog that contains arginine (positively charged R-group); this citrullinated peptide has been reported to induce T cell activation in DR4-IE transgenic mice (11). Therefore, the MS/MS spectra herein were searched carefully for evidence of peptides that could contain arginine-to-citrulline conversions. Our search algorithms assigned several peptides as forms containing citrulline residues.
- Asparagine deamidation in addition to being the product of biological processes, can also result from exposure of the sample to high temperature and/or low pH (68), the very conditions used to elute peptides from the MHC molecules, and thus this modification could, in some cases, be an artifact generated during sample processing.
- a library of citrullinated proteins has been compiled via LC-MS/MS analysis of RA patients' synovial tissue/fluid (69, 70). Manual search of our LC-MS/MS data according to this inventory did not result in the detection of any citrullinated HLA-DR- presented peptide.
- a principal advantage of autoantigen identification starting with an immunogenic T cell epitope is that it often focuses the search on more broadly applicable T and B cell responses in many patients that result in sustained high-titer autoantibodies, and these responses correlate with pathophysiological consequences.
- the identification of in vivo HLA-DR-presented peptides from PBMC which can be readily obtained from any patient, offers a precision, personalized approach for the identification of potentially pathogenic immune responses in a patient with any immune- mediated disease.
- LA patients met the 2010 criteria of the American College of Rheumatology/ European League against Rheumatism (ACR/EULAR) definition for the diagnosis of rheumatoid arthritis (50), and the eight LA patients met the criteria of the Centers for Disease Control and Prevention for the diagnosis of Lyme disease (51). All eight LA patients had antibiotic -refractory LA, defined as persistent arthritis for > three months after the start of > two months of appropriate oral antibiotic therapy and > one month of IV antibiotic therapy (52). In LA patients, synovial tissue was obtained at the time of therapeutic, arthroscopic synovectomies, and, in RA patients, the tissue was collected at the time of synovectomy or joint replacement surgery.
- ACR/EULAR American College of Rheumatology/ European League against Rheumatism
- ST, SFMC, and PBMC Preparation All the reagents were purchased from Sigma- Aldrich (St. Louis, MO) except where noted. ST samples (8-10 g) were prepared using the protocol described previously in reference (30), the contents of which are incorporated hereby in its entirety. Heparinized SFMC and PBMC ( ⁇ 3 to 8 x 10 7 cells) were obtained by Ficoll-Hypaque (MP Biomedicals) separation and stored in liquid nitrogen prior to analysis. On the day of purification, SFMC and PBMC samples were quickly thawed by placing in a 37 °C water bath for two minutes.
- LC -MS/MS High performance LC-MS/MS was performed on purified HLA-DR-presented peptides after desalting using C 18 ZipTip (Millipore, Billerica, MA). The methods used for each mass spectrometer are described below.
- LTQ-Orbitrap XL mass spectrometer A nanoAcquity UPLC system (Waters Corp., Milford, MA) was coupled to an LTQ-Orbitrap XL MS (ThermoFisher Scientific, San Jose, CA) through a TriVersa.
- NanoMate ion source (Advion, Ithaca, NY)— Peptide enrichment was performed with a trapping column (180 ⁇ m x 20 mm, 5 ⁇ m 100 A Symmetry Cig, Waters Corp) at a flow rate of 15 ⁇ L/min for 1 min, and separation was achieved with a capillary column ( 150 ⁇ m x 10 cm, 1.7 ⁇ m 130 A BEH C 18 , Waters Corp). Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN. A linear gradient of buffer B from 2% to 40% over 52 min was used at a flow rate of 0.5 ⁇ L/min.
- ACN acetonitrile
- buffer B contained 1% water and 0.1% formic acid in ACN.
- the capillary voltage was set to 1.7 kV using the NanoMate, and the capillary temperature was set to 120 °C.
- the mass spectra were recorded over the range m/z 300-2000 at a resolution of 60,000 (the width of the peak at half its maximum height at m/z 300) at a scan rate of approximately 1.2 s/spectrum. Tandem MS was performed for the five most abundant, multiply- charged species in the mass spectra that had a signal intensity threshold of 8000 NL.
- the normalized collision energy for CID was set to 35%, and helium was used as the collision gas.
- MS/MS spectra were recorded with the LTQ XL linear ion trap. All spectra were recorded in profile mode. Two to five LC-MS/MS runs were performed for each sample, and all the RAW files for each sample were combined into one Mascot generic file using Proteome
- Q Exactive plus mass spectrometer A nanoAcquity UPLC system was coupled to a Q Exactive plus MS (ThermoFisher Scientific, San Jose, CA) through a TriVersa NanoMate ion source. The same peptide enrichment and separation columns, HPLC solvents and gradients, and NanoMate capillary voltage and temperature used on the LTQ-Orbitrap XL MS were applied on the Q Exactive plus MS. Survey MS scans were recorded over the range m/z 400-2000 with a resolution of 70,000 (at m/z 300).
- 6550 iFunnel QTOF LC/MS Two 1260 HPLC systems were coupled to a 6550 iFunnel QTOF MS through a chip cube interface (Agilent Technologies, Santa Clara, CA). A Polaris-HR-3C18 chip was used for peptide enrichment and separation. The flow rate on the enrichment column was set at 2 ⁇ L/min with sample flush volume set as 4 ⁇ L.
- a gradient of buffer B (from 2% to 5% over 0.1 min, 5% to 20% over 74.9 min, 20% to 40% over 10 min, 40% to 90% over 10 min, held at 90% buffer B for 5 min, returned to 2% buffer B and held for 10 min) was used at a flow rate of 0.3 ⁇ / ⁇ for peptide separation.
- the capillary voltage was set to 1.7 to 1.95 kV, and the gas temperature was set to 225 °C.
- the survey mass spectra were recorded over the range m/z 295-1700 with acquisition rate of 8 spectra/second. Tandem mass spectra were recorded over the range m/z 50-1700 with an acquisition rate of 3 spectra/second.
- Precursor ion isolation was performed with a narrow isolation window of 1.3 m/z. Tandem MS was performed for the 20 most abundant, multiply- harged species in the mass spectra that had a signal intensity threshold of 5000 counts or a relative threshold of 0.001%.
- the collision energy for CID was set using the formula [3.1 x(m/z)/100+l] for doubly charged precursor ions and [3.6 x (m/z)/ 100-4.8] for triply and higher charged precursor ions.
- Active exclusion was enabled after recording one tandem spectrum and released after 0.15 min. All spectra were recorded in the centroid mode.
- One to two LC-MS/MS runs were performed for each sample, and all the data files for each sample were combined into one Mascot generic file using
- HLA-DR- presented self-peptides were identified by searching the Mascot generic file from each sample against the UniProt human database concatenated with a decoy database.
- the decoy databases were generated by randomizing each protein sequence in the database using the Perl script decoy.pl (Matrix Science).
- pyroglutamic acid from amino-terminal glutamine and glutamic acid, and oxidation of methionine were specified as the variable modifications in all searches.
- S-cysteinylated peptides have been identified in MHC class I- and class Il-presented peptides (53-56) and in our previous study (30).
- precursor ion error tolerance was set as 0.01 Da and fragment ion error tolerance was set as 0.5 Da; for data acquired using Q Exactive plus MS, precursor ion error tolerance was set as 10 ppm and fragment ion error tolerance was set as 20 mmu; for data acquired using 6550 iFunnel QTOF MS, precursor ion error tolerance was set as 20 ppm and fragment ion error tolerance was set as 50 mmu.
- "No enzyme" was specified for all the protein database searches. Mascot score cutoff was set at >20; OMSSA e-value cutoff was set to ⁇ 0.01 ; and X!Tandem e- value cutoff was set at ⁇ 10.
- Example 3 - ELISPOT assays can be performed with GNS and/or filamin A peptides suspected of being autoantigens in a subject.
- Enzyme-linked immunosorbent spot (ELISPOT) assays are performed using ELISpot plus for human IFN- ⁇ kits (Mabtech Inc., # 3420-2AW-Plus). Briefly, PBMC collected using Ficoll-Hypaque density centrifugation and stored in liquid nitrogen are thawed quickly and plated in round bottom, 96- well plates (Costar, # 3799) at 2 x 10 5 per well in 200 ⁇ of complete media (RPMI-1640, 2 mM glutamine, 100 units/ml penicillin 100 ⁇ g/ml streptomycin, 10 mM HEPES (all from Invitrogen) and 10% human AB serum (Cellgrow).
- complete media RPMI-1640, 2 mM glutamine, 100 units/ml penicillin 100 ⁇ g/ml streptomycin, 10 mM HEPES (all from Invitrogen) and 10% human AB serum (Cellgrow).
- Full length protein or shorter peptide fragments are added at a concentration of 1 ⁇ in duplicate wells. Positive and negative controls consist of 1% PHA (Invitrogen, # 10576-015) and no antigen, respectively. After 5 days at 37°C and 5% C0 2 , cells are transferred to ELISPOT plates (Mabtech), previously coated with IFN- ⁇ capture antibody, and incubated overnight. All subsequent steps are performed as detailed in the manufacturer's protocol. Images of wells are captured using ImmunoSpot series 3B analyzer and spots counted using ImmunoSpot 5.0 academic software (Cellular Technology Limited).
- Example 4 - ELISA assays can be performed with GNS and/or filamin A peptides suspected of being autoantigens in a subject.
- Serum anti-peptide antibody ELISA EasyWash ELISA plates (CoStar) are coated with 100 ⁇ of 0.5 ⁇ g/ml carrier free, recombinant human GNS and/or filamin A full length protein or peptide fragments dissolved in PBS and incubated overnight at 4°C. All subsequent steps are performed at room temperature with plates on a platform shaker set at 200 rpm.
- PBST phosphate buffered saline and 0.05% Tween-20
- blocking buffer 5% nonfat dry milk in PBST
- wells are washed three times with PBST and 100 ⁇ of each patient's serum sample diluted 1/100 with blocking buffer is added to individual wells and incubated for 1 hr.
- serum from eight healthy subjects is added to each plate to be used for inter-plate standardization.
- Synovial fluid autoantigen sandwich ELISA EasyWash ELISA plates are coated with 50 ⁇ of the capture antibody, goat anti-human autoantigen (human GNS and/or filamin A full length protein or peptide fragments) diluted in PBS (5 ⁇ g/ml) and incubated overnight at 4°C. All subsequent steps are performed at room temperature. The next day, plates are washed three times with PBS and incubated with blocking buffer for 30 min. Afterwards, plates are washed three times with PBS and 100 ⁇ of each patients' synovial fluid sample diluted 1 : 10 with blocking buffer are added to individual wells and incubated for 2 hr.
- recombinant human autoantigen serially diluted with blocking buffer is also added to each plate to generate a standard curve. After washing the plates three times, wells are filled with 150 ⁇ of blocking buffer, gently vortexed and washed again three times with PBS to ensure removal of all unbound proteins. Plates are then incubated with 50 ⁇ of the mouse anti- human autoantigen antibody diluted in blocking buffer (5 ng/ml) for 2 hr. Plates are again washed with PBS and 50 ⁇ of the detection antibody, goat anti-mouse IgG conjugated to horse radish peroxidase (Santa Cruz, #SC-2005) diluted in blocking buffer (1 : 1000) is added to plates and incubated for 1 hr. After plates are washed three times with PBS, 100 ⁇ of TMB was added for ⁇ 6 min and then the reaction is stopped with 100 ⁇ of 2N sulfuric acid. Plates are read as described above.
- Example 5 Immunoblotting can be performed with GNS and/or filamin A peptides suspected of being autoantigens in a subject.
- Autoantigen e.g, human GNS and/or filamin A full length protein or peptide fragments, such as human recombinant autoantigen
- 12 ⁇ g is electrophoresed through a 10% mini-PROTEAN TGX gels (Bio-Rad) then transferred to nitrocellulose membranes. All subsequent steps are performed at room temperature with rocking.
- Membranes are cut into strips, individually placed into eight channel reservoir liners (Costar, #4878) and incubated for 1 hr in 1.5 ml blocking buffer (5% nonfat dry milk, 0.1% Tween- 20 in 20 mM Tris, 500 mM sodium chloride; pH 7.5). Afterwards, strips are washed three times for 1 min intervals with rinse buffer (0.1% Tween-20 in 20 mM Tris, 500 mM sodium chloride; pH 7.5) and each individual strip is incubated for 1 hr with patient's serum diluted 1: 100 in blocking buffer.
- blocking buffer 5% nonfat dry milk, 0.1% Tween- 20 in 20 mM Tris, 500 mM sodium chloride; pH 7.5.
- Strips are again washed three times with rinse buffer and incubated for 1 hr with goat anti-human IgG antibody conjugated to alkaline phosphatase (KPL, #4751-1006) diluted 1 :2000 in blocking buffer. Strips are washed three times with rinse buffer and another three times with 20 mM Tris, 500 mM sodium chloride; pH 7.5. Bands are visualized by incubation with NBT/BCIP substrate solution (Roche Diagnostics GmbH, # 11681451001) for 3-5 min after which the strips are washed with copious amounts of water to stop the reaction. Bands are considered positive if darker than the pre -determined positive control sample included in each assay.
- Migliorini P. HLA shared epitope and ACPA: just a marker or an active player? Autoimmun Rev 2013, 12, 1182-1187.
- a novel human autoantigen, endothelial cell growth factor is a target of T and B cell responses in patients with Lyme disease Arthritis Rheum 2013, 65, 186-196.
- Annexin A2 is a target of T and B cell responses associated with synovial fibroblast proliferation in patients with antibiotic-refractory Lyme arthritis. Clin Immunol 2015, 160, 336-341.
- Intra-articular CDlc-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Thl, Thl 7 and Th2 cell activity Arthritis Res Ther 2013, 75, R155. 29.
- HLA-A* 0201 -restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition Immunity 1997, 6, 273-281.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016261939A AU2016261939A1 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for diagnosis of rheumatoid arthritis |
JP2018511342A JP6663000B2 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for the diagnosis of rheumatoid arthritis |
US15/571,734 US10429379B2 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for diagnosis of rheumatoid arthritis |
EP16793518.8A EP3294901B1 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for diagnosis of rheumatoid arthritis |
CA2985637A CA2985637A1 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for diagnosis of rheumatoid arthritis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160320P | 2015-05-12 | 2015-05-12 | |
US62/160,320 | 2015-05-12 | ||
US201562162295P | 2015-05-15 | 2015-05-15 | |
US62/162,295 | 2015-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016183310A1 true WO2016183310A1 (en) | 2016-11-17 |
Family
ID=57248470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/032077 WO2016183310A1 (en) | 2015-05-12 | 2016-05-12 | Autoantigens for diagnosis of rheumatoid arthritis |
Country Status (6)
Country | Link |
---|---|
US (1) | US10429379B2 (en) |
EP (1) | EP3294901B1 (en) |
JP (1) | JP6663000B2 (en) |
AU (1) | AU2016261939A1 (en) |
CA (1) | CA2985637A1 (en) |
WO (1) | WO2016183310A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214180A1 (en) | 2016-06-07 | 2017-12-14 | The General Hospital Corporation | Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis |
US20180284118A1 (en) * | 2017-04-04 | 2018-10-04 | The Johns Hopkins University | Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases |
WO2019009231A1 (en) * | 2017-07-06 | 2019-01-10 | 国立大学法人筑波大学 | Diagnostic of rheumatoid arthritis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
WO2005029091A2 (en) | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
US20050130117A1 (en) * | 2001-10-03 | 2005-06-16 | Davis Cong L. | Modulators of lymphocyte activation and migration |
WO2005064307A2 (en) | 2003-12-23 | 2005-07-14 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6 |
WO2005085858A1 (en) | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a |
WO2006008183A1 (en) | 2004-07-23 | 2006-01-26 | Novartis Ag | Biomarkers for rheumatoid arthritis (ra) |
WO2007039280A1 (en) | 2005-10-06 | 2007-04-12 | Roche Diagnostics Gmbh | Anti-ccp and antinuclear antibodies in diagnosis of rheumatoid arthritis |
US20130302329A1 (en) * | 2010-09-21 | 2013-11-14 | Trustees Of Boston University | Diagnostic tests for immune reactivity with human endothelial cell growth factor |
US20150010631A1 (en) * | 2013-03-13 | 2015-01-08 | Cour Pharmaceuticals Development Company | Immune-modifying nanoparticles for the treatment of inflammatory diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
IT1105734B (en) * | 1977-07-14 | 1985-11-04 | Syva Co | TEST OF COMPETITION LINK OF HOMOGENEOUS ANTI-ENZYME |
US5248595A (en) | 1991-10-08 | 1993-09-28 | Eastman Kodak Company | Wash composition, test kit and method for determination of microorganisms associated with periodontal diseases |
WO2002048310A2 (en) * | 2000-12-15 | 2002-06-20 | Genetics Institute, Llc | Methods and compositions for diagnosing and treating rheumatoid arthritis |
AU2004216925B2 (en) * | 2003-03-07 | 2010-04-22 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecules involved in autoimmune diseases |
CA2772929A1 (en) | 2009-09-03 | 2011-03-11 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
ES2574790T3 (en) * | 2011-07-01 | 2016-06-22 | Inova Diagnostics, Inc. | Procedure to increase the specificity of diagnostic tests for autoimmune diseases |
EP3463441B1 (en) | 2016-06-07 | 2023-10-25 | The General Hospital Corporation | Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis |
-
2016
- 2016-05-12 JP JP2018511342A patent/JP6663000B2/en active Active
- 2016-05-12 WO PCT/US2016/032077 patent/WO2016183310A1/en active Application Filing
- 2016-05-12 US US15/571,734 patent/US10429379B2/en active Active
- 2016-05-12 EP EP16793518.8A patent/EP3294901B1/en active Active
- 2016-05-12 AU AU2016261939A patent/AU2016261939A1/en not_active Abandoned
- 2016-05-12 CA CA2985637A patent/CA2985637A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
US20050130117A1 (en) * | 2001-10-03 | 2005-06-16 | Davis Cong L. | Modulators of lymphocyte activation and migration |
WO2005029091A2 (en) | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
US20060094056A1 (en) | 2003-09-15 | 2006-05-04 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases |
WO2005064307A2 (en) | 2003-12-23 | 2005-07-14 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6 |
US20070264673A1 (en) | 2003-12-23 | 2007-11-15 | Nobert Wild | Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6 |
WO2005085858A1 (en) | 2004-02-27 | 2005-09-15 | Roche Diagnostics Gmbh | Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a |
WO2006008183A1 (en) | 2004-07-23 | 2006-01-26 | Novartis Ag | Biomarkers for rheumatoid arthritis (ra) |
WO2007039280A1 (en) | 2005-10-06 | 2007-04-12 | Roche Diagnostics Gmbh | Anti-ccp and antinuclear antibodies in diagnosis of rheumatoid arthritis |
US20070148704A1 (en) | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
US20130302329A1 (en) * | 2010-09-21 | 2013-11-14 | Trustees Of Boston University | Diagnostic tests for immune reactivity with human endothelial cell growth factor |
US20150010631A1 (en) * | 2013-03-13 | 2015-01-08 | Cour Pharmaceuticals Development Company | Immune-modifying nanoparticles for the treatment of inflammatory diseases |
Non-Patent Citations (90)
Title |
---|
"Methods in Cell Biology", vol. 57, 1998, ACADEMIC PRESS, article "Animal Cell Culture Methods" |
ALETAHA DNEOGI TSILMAN AJ ET AL.: "Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative", ANN RHEUM DIS, vol. 69, 2010, pages 1580 - 1588 |
ALETAHA, D.NEOGI, T.SILMAN, A. J.FUNOVITS, J.FELSON, D. T.BINGHAM, C. O.BIRNBAUM, N. S.BURMESTER, G. R.BYKERK, V. P.COHEN, M. D.: "Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative", ARTHRITIS RHEUM, vol. 62, 2010, pages 2569 - 2581 |
ALVAREZ-NAVARRO, C.CRAGNOLINI, J. J.DOS SANTOS, H. G.BARNEA, E.ADMON, A.MORREALE, A.LOPEZ DE CASTRO, J. A.: "Novel HLA-B27-restricted epitopes from Chlamydia trachomatis generated upon endogenous processing of bacterial proteins suggest a role of molecular mimicry in reactive arthritis", J BIOL CHEM, vol. 288, 2013, pages 25810 - 25825 |
ARNETT FCEDWORTHY SMBLOCH DA ET AL.: "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", ARTHRITIS RHEUM., vol. 31, 1988, pages 315 - 324 |
ASQUITH DLMILLER AMMCINNES IBLIEW FY.: "Animal models of rheumatoid arthritis", EUR J IMMUNOL., vol. 39, no. 8, August 2009 (2009-08-01), pages 2040 - 4 |
BASSANI-STERNBERG, M.BARNEA, E.BEER, I.AVIVI, I.KATZ, T.ADMON, A.: "Soluble plasma HLA peptidome as a potential source for cancer biomarkers", PROC NATL ACAD SCI U S A, vol. 107, 2010, pages 18769 - 18776 |
BASSANI-STERNBERG, M.PLETSCHER-FRANKILD, S.JENSEN, L. J.MANN, M.: "Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation", MOL CELL PROTEOMICS, vol. 14, 2015, pages 658 - 673, XP055272560, DOI: 10.1074/mcp.M114.042812 |
BEHERA, A. K.HILDEBRAND, E.SZAFRANSKI, J.HUNG, H. H.GRODZINSKY, A. J.LAFYATIS, R.KOCH, A. E.KALISH, R.PERIDES, G.STEERE, A. C.: "Role of aggrecanase 1 in Lyme arthritis", ARTHRITIS RHEUM, vol. 54, 2006, pages 3319 - 3329 |
BERGLIN, E.JOHANSSON, T.SUNDIN, U.JIDELL, E.WADELL, G.HALLMANS, G.RANTAPAA-DAHLQVIST, S.: "Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset", ANN RHEUM DIS, vol. 65, 2006, pages 453 - 458, XP002490250, DOI: 10.1136/ard.2005.041376 |
BIEMANN, K.: "Appendix 5. Nomenclature for peptide fragment ions (positive ions", METHODS ENZYMOL, vol. 193, 1990, pages 886 - 887 |
BOWIE ET AL., SCIENCE, vol. 247, 1990, pages 1306 |
BURKHARDT, H.SEHNERT, B.BOCKERMANN, R.ENGSTROM, A.KALDEN, J. R.HOLMDAHL, R.: "Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis", EUR J IMMUNOL, vol. 35, 2005, pages 1643 - 1652, XP055270128, DOI: 10.1002/eji.200526000 |
CARON, E.ESPONA, L.KOWALEWSKI, D. J.SCHUSTER, H.TERNETTE, N.ALPIZAR, A.SCHITTENHELM, R. B.RAMARATHINAM, S. H.LINDESTAM ARLEHAMN, C: "An open-source computational and data resource to analyze digital maps of immunopeptidomes", ELIFE, vol. 4, 2015, XP055207421, DOI: 10.7554/eLife.07661 |
CARON, E.KOWALEWSKI, D. J.CHIEK KOH, C.STURM, T.SCHUSTER, H.AEBERSOLD, R.: "Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry", MOL CELL PROTEOMICS, vol. 14, 2015, pages 3105 - 3117, XP055609705, DOI: 10.1074/mcp.O115.052431 |
CHEN, W.YEWDELL, J. W.LEVINE, R. L.BENNINK, J. R.: "Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants", J EXP MED, vol. 189, 1999, pages 1757 - 1764 |
CHICZ, R. M.URBAN, R. G.GORGA, J. C.VIGNALI, D. A.LANE, W. S.STROMINGER, J. L.: "Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles", J EXP MED, vol. 178, 1993, pages 27 - 47, XP002069888, DOI: 10.1084/jem.178.1.27 |
CHOTHIALESK: "Relation between the divergence of sequence & structure in proteins", EMBO J., vol. 5, 1986, pages 823, XP008040109 |
CLORE ET AL., CRIT. REV. BIOCH. MOLEC. BIOL., vol. 24, 1989, pages 479 |
COBBOLD, M.DE LA PENA, H.NORRIS, A.POLEFRONE, J. M.QIAN, J.ENGLISH, A. M.CUMMINGS, K. LPENNY, S.TURNER, J. E.COTTINE, J.: "MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia", SCI TRANSLMED, vol. 5, 2013, pages 203ra125, XP055532847, DOI: 10.1126/scitranslmed.3006061 |
COLLADO, J. A.ALVAREZ, I.CIUDAD, M. T.ESPINOSA, G.CANALS, F.PUJOL-BORRELL, R.CARRASCAL, M.ABIAN, J.JARAQUEMADA, D.: "Composition of the HLA-DR-associated human thymus peptidome", EUR J IMMUNOL, vol. 43, 2013, pages 2273 - 2282 |
COOKE ET AL., BIOASSAYS, vol. 8, 1988, pages 52 |
CROWLEY, J. T.DROUIN, E. E.PIANTA, A.STRLE, K.WANG, Q.COSTELLO, C. E.STEERE, A. C. A: "highly expressed human protein, apolipoprotein B-100, serves as an autoantigen in a subgroup of patients with Lyme disease", JLNFECTDIS, 2015 |
CROWLEY, J. T.STRLE, K.DROUIN, E. E.PIANTA, A.ARVIKAR, S. L.WANG, Q.COSTELLO, C. E.STEERE, A. C.: "Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis", JAUTOIMMUN., vol. 69, 2016, pages 24 - 37, XP029494658, DOI: 10.1016/j.jaut.2016.02.005 |
CUNNINGHAM ET AL., SCIENCE, vol. 243, 1989, pages 1081 |
DE VRIES-BOUWSTRA, J. K.GOEKOOP-RUITERMAN, Y. P.VERPOORT, K. N.SCHREUDER, G. M.EWALS, J. A.TERWIEL, J. PRONDAY, H. K.KERSTENS, P. : "Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB 1, rheumatoid factor, and anti- citrullinated protein antibodies in relation to different treatment strategies", ARTHRITIS RHEUM, vol. 58, 2008, pages 1293 - 1298, XP002498678, DOI: 10.1002/art.23439 |
DENGJEL, J.NASTKE, M. D.GOUTTEFANGEAS, C.GITSIOUDIS, G.SCHOOR, O.ALTENBEREND, F.MULLER, M.KRAMER, B.MISSIOU, A.SAUTER, M.: "Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas", CLIN CANCER RES, vol. 12, 2006, pages 4163 - 4170 |
DEUTSCHER, METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 83 - 9 |
DROUIN, E. E.SEWARD, R. J.STRLE, K.MCHUGH, G.KATCHAR, K.LONDONO, D.YAO, C.COSTELLO, C. E.STEERE, A. C.: "A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease", ARTHRITIS RHEUM, vol. 65, 2013, pages 186 - 196, XP055104144, DOI: 10.1002/art.37732 |
GORDON, R. D.YOUNG, J. A.RAYNER, S.LUKE, R. W.CROWTHER, M. L.WORDSWORTH, P.BELL, J.HASSALL, G.EVANS, J.HINCHLIFFE, S. A. ET AL.: "Purification and characterization of endogenous peptides extracted from HLA-DR isolated from the spleen of a patient with rheumatoid arthritis", EUR JLMMUNOL, vol. 25, 1995, pages 1473 - 1476 |
GREGERSEN, P. K.SILVER, J.WINCHESTER, R. J.: "The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis", ARTHRITIS RHEUM, vol. 30, 1987, pages 1205 - 1213 |
GUASP, P.ALVAREZ-NAVARRO, C.GOMEZ-MOLINA, P.MARTIN-ESTEBAN, AMARCILLA, M.BARNEA, E.ADMON, A.LOPEZ DE CASTRO, J. A.: "The Peptidome of Behcet's Disease-Associated HLA-B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1", ARTHRITIS & RHEUMATOLOGY, vol. 68, 2016, pages 505 - 515 |
HAQUE, M. A.HAWES, J. W.BLUM, J. S.: "Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition", JLMMUNOL, vol. 166, 2001, pages 4543 - 4551, XP002716245, DOI: 10.4049/jimmunol.166.7.4543 |
HILL, J. A.SOUTHWOOD, S.SETTE, A.JEVNIKAR, A. M.BELL, D. A.CAIRNS, E.: "Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule", JLMMUNOL, vol. 171, 2003, pages 538 - 541 |
HOLOSHITZ, J.: "The rheumatoid arthritis HLA-DRB1 shared epitope", CURR OPIN RHEUMATOL, vol. 22, 2010, pages 293 - 298 |
HUIZINGA, T. W.AMOS, C. I.VAN DER HELM-VAN MIL, A. H.CHEN, W.VAN GAALEN, F. A.JAWAHEER, D.SCHREUDER, G. M.WENER, M.BREEDVELD, F. C: "Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins", ARTHRITIS RHEUM, vol. 52, 2005, pages 3433 - 3438 |
HUNT, D. F.HENDERSON, R. A.SHABANOWITZ, J.SAKAGUCHI, K.MICHEL, H.SEVILIR, N.COX, A. L.APPELLA, E.ENGELHARD, V. H.: "Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry", SCIENCE, vol. 255, 1992, pages 1261 - 1263, XP002970509, DOI: 10.1126/science.1546328 |
KATCHAR, K.DROUIN, E. E.STEERE, A. C.: "Natural killer cells and natural killer T cells in Lyme arthritis", ARTHRITIS RES THER, vol. 15, 2013, pages R183, XP021169108, DOI: 10.1186/ar4373 |
KINLOCH, A.TATZER, V.WAIT, R.PESTON, DLUNDBERG, K.DONATIEN, P.MOYES, D.TAYLOR, P. C.VENABLES, P. J.: "Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis", ARTHRITIS RES THER, vol. 7, 2005, pages R1421 - 1429, XP021011685 |
LI, Y.DEPONTIEU, F. R.SIDNEY, J.SALAY, T. M.ENGELHARD, V. H.HUNT, D. F.SETTE, A.TOPALIAN, S. L.MARIUZZA, R. A.: "Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells", J MOL BIOL, vol. 399, 2010, pages 596 - 603, XP027101403, DOI: 10.1016/j.jmb.2010.04.037 |
LIN ET AL., BMC IMMUNOLOGY, vol. 9, 2008, pages 8 |
LING, S.CLINE, E. N.HAUG, T. S.FOX, D. A.HOLOSHITZ, J.: "Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling", ARTHRITIS RHEUM, vol. 65, 2013, pages 618 - 626 |
LIPPOLIS, J. D.WHITE, F. M.MARTO, J. A.LUCKEY, C. J.BULLOCK, T. N.SHABANOWITZ, J.HUNT, D. F.ENGELHARD, V. H.: "Analysis of MHC class II antigen processing by quantitation of peptides that constitute nested sets", JLMMUNOL, vol. 169, 2002, pages 5089 - 5097 |
LONDONO, D.CADAVID, D.DROUIN, E. E.STRLE, K.MCHUGH, G.AVERSA, J. M.STEERE, A. C.: "Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis", ARTHRITIS & RHEUMATOLOGY, vol. 66, 2014, pages 2124 - 2133 |
MCDEVITT, H. O.BODMER, W. F. HL-A: "immune-response genes, and disease", LANCET, vol. 1, 1974, pages 1269 - 1275 |
MEADOWS, LWANG, W.DEN HAAN, J. M.BLOKLAND, E.REINHARDUS, C.DRIJFHOUT, J. W.SHABANOWITZ, J.PIERCE, R.AGULNIK, A. I.BISHOP, C. E.: "The HLA-A* 0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition", IMMUNITY, vol. 6, 1997, pages 273 - 281, XP055079719, DOI: 10.1016/S1074-7613(00)80330-1 |
MORET, F. M.HACK, C. E.VAN DER WURFF-JACOBS, K. M.DE JAGER, W.RADSTAKE, T. R.LAFEBER, F. P.VAN ROON, J. A.: "Intra-articular CDlc-expressing myeloid dendritic cells from rheumatoid arthritis patients express a unique set of T cell-attracting chemokines and spontaneously induce Thl, Th17 and Th2 cell activity", ARTHRITIS RES THER, vol. 15, 2013, pages R155 |
MUIXI, L.CARRASCAL, M.ALVAREZ, I.DAURA, X.MARTI, M.ARMENGOL, M. P.PINILLA, C.ABIAN, J.PUJOL-BORRELL, R.JARAQUEMADA, D.: "Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands", J IMMUNOL, vol. 181, 2008, pages 795 - 807 |
OSHITANI, N.HATO, F.KITAGAWA, S.MAEDA, K.HIGUCHI, K.MATSUMOTO, T.ARAKAWA, T.: "Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease", INT J MOL MED, vol. 11, 2003, pages 99 - 104 |
PACE, A. L.WONG, R. L.ZHANG, Y. T.KAO, Y. H.WANG, Y. J.: "Asparagine deamidation dependence on buffer type, pH, and temperature", JPHARM SCI, vol. 102, 2013, pages 1712 - 1723 |
PIANTA, A.DROUIN, E. E.CROWLEY, J. T.ARVIKAR, S.STRLE, K.COSTELLO, C. E.STEERE, A. C.: "Annexin A2 is a target of T and B cell responses associated with synovial fibroblast proliferation in patients with antibiotic-refractory Lyme arthritis", CLIN IMMUNOL, vol. 160, 2015, pages 336 - 341 |
PIANTA, A.DROUIN, E. EWANG, Q.ARVIKAR, S.COSTELLO, C. E.STEERE, A. C.: "Identification of N-acetylglucosamine-6-sulfatase and filamin A as novel targets of autoimmune T and B cell responses in rheumatoid arthritis", ANN RHEUM DIS, vol. 74S, 2015, pages 112 |
PIERCE, R. A.FIELD, E. D.DEN HAAN, J. M.CALDWELL, J. A.WHITE, F. M.MARTO, J. A.WANG, W.FROST, L. M.BLOKLAND, E.REINHARDUS, C.: "Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique", J IMMUNOL, vol. 163, 1999, pages 6360 - 6364 |
PLENGE, R. M.: "Rheumatoid arthritis genetics", CURR RHEUMATOL REP, vol. 11, 2009, pages 351 - 356 |
PRATESI, F.PETIT TEIXEIRA, E.SIDNEY, J.MICHOU, L.PUXEDDU, I.SETTE, A.CORNELIS, F.MIGLIORINI, P.: "HLA shared epitope and ACPA: just a marker or an active player?", AUTOIMMUN REV, vol. 12, 2013, pages 1182 - 1187 |
RATTAN ET AL., ANN. N.Y. ACAD. SCI., vol. 663, 1992, pages 48 |
SALLE, V.MAZIERE, J. C.SMALL, A.CEVALLOS, R.MAZIERE, CFUENTES, V.TRAMIER, B.MAKDASSI, R.CHOUKROUN, G.VITTECOQ, O.: "Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome", J CLIN IMMUNOL, vol. 28, 2008, pages 291 - 297, XP019608240 |
SCHULZ ET AL.: "Principles of Protein Structure", 1979, SPRINGER-VERLAG, pages: 14 - 16 |
SCOPES: "Protein Purification: Principles and Practice", 1982, SPRINGER-VERLAG |
See also references of EP3294901A4 |
SEIFTER ET AL., METH. ENZYMOL., vol. 182, 1990, pages 626 |
SEWARD, R. J.DROUIN, E. E.STEERE, A. C.COSTELLO, C. E.: "Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis", MOL CELL PROTEOMICS, vol. 10, 2011, pages M110 002477 |
SHEN, S.SHIN, J. J.STRLE, K.MCHUGH, G.LI, X.GLICKSTEIN, L. J.DROUIN, E. E.STEERE, A. C.: "Treg cell numbers and function in patients with antibiotic-refractory or antibioticresponsive Lyme arthritis", ARTHRITIS RHEUM, vol. 62, 2010, pages 2127 - 2137, XP055096804, DOI: 10.1002/art.27468 |
SHIN, J. J.GLICKSTEIN, L. J.STEERE, A. C.: "High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory lyme arthritis", ARTHRITIS RHEUM, vol. 56, 2007, pages 1325 - 1335 |
SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 |
SNIR, O.WIDHE, M.VON SPEE, C.LINDBERG, J.PADYUKOV, L.LUNDBERG, K.ENGSTROM, A.VENABLES, P. J.LUNDEBERG, J.HOLMDAHL, R.: "Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles", ANN RHEUM DIS, vol. 68, 2009, pages 736 - 743 |
SPENGLER, J.LUGONJA, B.YTTERBERG, A. J.ZUBAREV, R. A.CREESE, A. J.PEARSON, M. J.GRANT, M. M.MILWARD, M.LUNDBERG, K.BUCKLEY, C. D.: "Release of Active Peptidyl Arginine Deiminases by Neutrophils Can Explain Production of Extracellular Citrullinated Autoantigens in Rheumatoid Arthritis Synovial Fluid", ARTHRITIS & RHEUMATOLOGY, vol. 67, 2015, pages 3135 - 3145 |
STEERE, A. C.: "Lyme disease", N ENGL J MED, vol. 345, 2001, pages 115 - 125 |
STEERE, A. C.ANGELIS, S. M.: "Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis", ARTHRITIS RHEUM, vol. 54, 2006, pages 3079 - 3086 |
STEERE, A. C.DURAY, P. H.BUTCHER, E. C.: "Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue", ARTHRITIS RHEUM, vol. 31, 1988, pages 487 - 495 |
STEERE, A. C.GLICKSTEIN, L.: "Elucidation of Lyme arthritis", NAT REV 7, vol. 4, 2004, pages 143 - 152 |
STEERE, A. C.KLITZ, W.DROUIN, E. E.FALK, B. A.KWOK, W. W.NEPOM, G. T.BAXTER-LOWE, L. A.: "Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide", J EXP MED, vol. 203, 2006, pages 961 - 971, XP002632126, DOI: 10.1084/JEM.20052471 |
STEERE, A. C.LEVIN, R. E.MOLLOY, P. J.KALISH, R. A.ABRAHAM, J. H.LIU, N. Y.SCHMID, C. H.: "Treatment of Lyme arthritis", ARTHRITIS RHEUM, vol. 37, 1994, pages 878 - 888 |
STEERE, A. C.SCHOEN, R. T.TAYLOR, E.: "The clinical evolution of Lyme arthritis", ANN INTERN MED, vol. 107, 1987, pages 725 - 731 |
STEFANOVA, I.DORFMAN, J. R.TSUKAMOTO, M.GERMAIN, R. N.: "On the role of self- recognition in T cell responses to foreign antigen", IMMUNOL REV, vol. 191, 2003, pages 97 - 106 |
STRLE, K.SHIN, J. J.GLICKSTEIN, L. J.STEERE, A. C.: "Association of a Toll-like receptor 1 polymorphism with heightened Thl inflammatory responses and antibiotic-refractory Lyme arthritis", ARTHRITIS RHEUM, vol. 64, 2012, pages 1497 - 1507 |
STURNIOLO ET AL., NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 555 - 561 |
TAKEMURA, S.BRAUN, A.CROWSON, C.KURTIN, P. J.COFIELD, R. H.O'FALLON, W. M.GORONZY, J. J.WEYAND, C. M.: "Lymphoid neogenesis in rheumatoid synovitis", JLMMUNOL, vol. 167, 2001, pages 1072 - 1080 |
TAKIZAWA, Y.SUZUKI, A.SAWADA, T.OHSAKA, M.INOUE, T.YAMADA, R.YAMAMOTO, K.: "Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids", ANN RHEUM DIS, vol. 65, 2006, pages 1013 - 1020, XP009161230, DOI: 10.1136/ard.2005.044743 |
VAN BEERS, J. J.SCHWARTE, C. M.STAMMEN-VOGELZANGS, J.OOSTERINK, E.BOZIC, B.PRUIJN, G. J.: "The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin", ARTHRITIS RHEUM, vol. 65, 2013, pages 69 - 80 |
VAN BEERS, J. J.WILLEMZE, A.STAMMEN-VOGELZANGS, J.DRIJFHOUT, J. W.TOES, R. E.PRUIJN, G. J.: "Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRBl shared epitope alleles", ARTHRITIS RES THER, vol. 14, 2012, pages R35, XP021119727, DOI: 10.1186/ar3744 |
VIZCAINO, J. A.DEUTSCH, E. W.WANG, R.CSORDAS, A.REISINGER, F.RIOS, D.DIANES, J. A.SUN, Z.FARRAH, T.BANDEIRA, N.: "ProteomeXchange provides globally coordinated proteomics data submission and dissemination", NAT BIOTECHNOL, vol. 32, 2014, pages 223 - 226 |
VOSSENAAR, E. R.DESPRES, N.LAPOINTE, E.VAN DER HEIJDEN, A.LORA, M.SENSHU, T.VAN VENROOIJ, W. J.MENARD, H. A.: "Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin", ARTHRITIS RES THER, vol. 6, 2004, pages R142 - 150, XP021011474, DOI: 10.1186/ar1149 |
VUDATTU, N. K.STRLE, K.STEERE, A. C.DROUIN, E. E.: "Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis", ARTHRITIS RHEUM, vol. 65, 2013, pages 1643 - 1653 |
WAHLSTROM, J.DENGJEL, J.PERSSON, B.DUYAR, H.RAMMENSEE, H. G.STEVANOVIC, S.EKLUND, A.WEISSERT, R.GRUNEWALD, J.: "Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis", J CLIN INVEST, vol. 117, 2007, pages 3576 - 3582 |
WHARTON, M.CHORBA, T. L.VOGT, R. L.MORSE, D. L.BUEHLER, J. W.: "Case definitions for public health surveillance", MMWR RECOMM REP, vol. 39, 1990, pages 1 - 43 |
WOLD: "POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS", vol. 1-12, 1983, ACADEMIC PRESS |
WUTHRICH: "NMR of Proteins & Nucleic Acids", 1986, WILEY |
YTTERBERG, A. J.JOSHUA, V.REYNISDOTTIR, G.TARASOVA, N. K.RUTISHAUSER, D.OSSIPOVA, E.HAJ HENSVOLD, AEKLUND, A.SKOLD, C. M.GRUNEWALD: "Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation", ANN RHEUM DIS, vol. 74, 2015, pages 1772 - 1777 |
ZHANG, B.PIRMORADIAN, M.CHERNOBROVKIN, A.ZUBAREV, R. A.: "DeMix workflow for efficient identification of cofragmented peptides in high resolution data-dependent tandem mass spectrometry", MOL CELL PROTEOMICS, vol. 13, 2014, pages 3211 - 3223 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214180A1 (en) | 2016-06-07 | 2017-12-14 | The General Hospital Corporation | Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis |
US20180284118A1 (en) * | 2017-04-04 | 2018-10-04 | The Johns Hopkins University | Anti-pad2 antibody for treating and evaluating autoimmune and inflammatory diseases |
WO2019009231A1 (en) * | 2017-07-06 | 2019-01-10 | 国立大学法人筑波大学 | Diagnostic of rheumatoid arthritis |
JPWO2019009231A1 (en) * | 2017-07-06 | 2020-07-30 | 国立大学法人 筑波大学 | Rheumatoid arthritis diagnostic |
JP7202010B2 (en) | 2017-07-06 | 2023-01-11 | 国立大学法人 筑波大学 | Rheumatoid arthritis diagnostic agent |
Also Published As
Publication number | Publication date |
---|---|
EP3294901B1 (en) | 2023-05-03 |
US20180156778A1 (en) | 2018-06-07 |
AU2016261939A1 (en) | 2018-01-04 |
US10429379B2 (en) | 2019-10-01 |
CA2985637A1 (en) | 2016-11-17 |
JP6663000B2 (en) | 2020-03-11 |
EP3294901A4 (en) | 2018-11-21 |
JP2018517151A (en) | 2018-06-28 |
EP3294901A1 (en) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Volkov et al. | Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology | |
Harre et al. | Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin | |
Wang et al. | Immunogenic HLA-DR-presented self-peptides identified directly from clinical samples of synovial tissue, synovial fluid, or peripheral blood in patients with rheumatoid arthritis or lyme arthritis | |
Sokolova et al. | Autoantibodies in rheumatoid arthritis: historical background and novel findings | |
US20210405047A1 (en) | Anti-carbamylated protein antibodies and the risk for arthritis | |
JP5998318B2 (en) | New vasculitis test method and test reagent | |
US20210247391A1 (en) | Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rehumatoid arthritis | |
EP3294901B1 (en) | Autoantigens for diagnosis of rheumatoid arthritis | |
Routsias et al. | Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response | |
Cantagrel et al. | New autoantibodies associated with rheumatoid arthritis recognize posttranslationally modified self-proteins | |
WO2016003719A1 (en) | Autoantigens for diagnosis of chronic inflammatory diseases | |
Bridges Jr | Update on autoantibodies in rheumatoid arthritis | |
EP2619579B1 (en) | Diagnostic tests for immune reactivity with human endothelial cell growth factor | |
US20180313830A1 (en) | Peptide and biomarker associated with inflammatory disorders, and uses thereof | |
Mahler et al. | Challenges and controversies in autoantibodies associated with systemic rheumatic diseases | |
Houtman et al. | Fluctuations in anti-nRNP levels in patients with mixed connective tissue disease are related to disease activity as part of a polyclonal B cell response. | |
JP6536944B2 (en) | Method for determining cells involved in onset of autoimmune disease and use thereof | |
Trier et al. | Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis | |
Dekkers | Tolerance and immune regulation in rheumatoid arthritis | |
Téllez et al. | Autoanticuerpos para diagnóstico y pronóstico en artrtis reumatoide: inmunoensayo cubano con péptido citrulinado del fibrinógeno | |
Téllez et al. | Autoantibodies for diagnostic and prognosis in rheumatoid arthritis: Cuban immunoassay with citrullinated fibrinogen peptide | |
JP2012224594A (en) | Cyclic citrullinated glucose-6-phosphate isomerase peptide and method for diagnosing rheumatoid arthritis | |
Reed | Study of Autoimmune Reactions in Rheumatoid Arthritis | |
Tutturen | Enrichment and identification of citrullinated proteins in biological samples | |
Steinman et al. | Autoimmunity against Fibrinogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16793518 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2985637 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2018511342 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016793518 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2016261939 Country of ref document: AU Date of ref document: 20160512 Kind code of ref document: A |